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POLICY
The ‘thousand-dollar genome’: an ethical exploration
Wybo J Dondorp*,1 and Guido MWR de Wert1
Sequencing an individual’s complete genome is expected to be possible for a relatively low sum ‘one thousand dollars’ within
a few years. Sequencing refers to determining the order of base pairs that make up the genome. The result is a library of
three billion letter combinations. Cheap whole-genome sequencing is of greatest importance to medical scientific research.
Comparing individual complete genomes will lead to a better understanding of the contribution genetic variation makes to health
and disease. As knowledge increases, the ‘thousand-dollar genome’ will also become increasingly important to healthcare.
The applications that come within reach raise a number of ethical questions. This monitoring report addresses the issue.
European Journal of Human Genetics (2013) 21, S6–S26; doi:10.1038/ejhg.2013.73
SUMMARY
Analysing the entire human genome
Whole-genome sequencing (WGS) can lead to whole-genome analysis
(WGA), in which the meaning of the raw data obtained during
sequencing is fleshed out. This is done using software integrating
the latest scientific insights into the relationship between genes and
health. Filters may be used to selectively examine certain parts of the
genome (targeted analysis), for example when diagnosing diseases
with a known genetic substrate. Use of filters helps limit the amount of
non-relevant information. Using this approach, WGS-based diagnostic
testing yields results that are not different from diagnostic testing with
existing methods, such as DNA chips. If WGS becomes cheap enough
in future, it will likely become the standard approach.
Diagnostic testing
WGA (complete sequence analysis) is also expected to play a role in
healthcare, specifically in the diagnosis of diseases for which the genetic
background is not yet (or insufficiently) clear. Searching the entire
genome will often allow a diagnosis to be made. This approach was
recently already implemented, but using less powerful techniques.
Genome-wide diagnostic testing inevitably means that far more genetic
information about the patient is revealed than is necessary for
answering the clinical question. Among other things, this raises questions
about the feasibility of informed consent, the possibility to shape the
‘right not to know’ and the limits to the requirement to inform patients.
What should happen with the (raw) sequencing data afterwards? Should
it be stored? Is it allowed to be destroyed? What about the analysis
findings (genetic information): should all unsought for findings also be
saved? What about genetic information not desired by the patient, and
therefore not supplied to him or her? Finally: can a doctor be expected to
recontact the patient if new scientific knowledge means that data
obtained from past WGA may be viewed in a new light?
Screening
Some commentators expect that WGS and WGA for every individual
will be worthwhile in a few years. This would be performed without a
concrete medical indication, meaning it is screening rather than
diagnostic testing. Whole-genome screening creates a personal genomic
database (personal genome) that can subsequently be used to deliver
‘personalised medicine’ to individual patients. While the first steps in
this direction have already been taken (particularly in the field of
pharmacogenetics: ‘personalised medication’), this largely remains
something for the future. According to some, analysing the personal
genome would ideally be done when people reach the legal age. The
individual can then decide for himself whether or not to take part in
this form of screening, and it is still early enough in life to benefit
sufficiently. The usefulness may consist of lifestyle advice, treatment and
prevention tailored to the personal health profile, but also of risk
information that could affect reproductive decisions. In addition to
the (currently largely hypothetical) advantages of analysing the
personal genome, there are also all too real disadvantages to obtaining
information that could burdensome or even harmful. Disadvantages
include worry caused by (still) unclear findings and the resulting – often
unnecessary – contacts with healthcare. As long as there is no clear
positive balance of advantages and disadvantages, there can be no
responsible implementation of whole genome population screening
within public healthcare. However, as soon as WGS/WGA becomes
cheap enough, commercial parties will likely see a market. Whole-
genome tests are already commercially available, albeit currently imple-
menting methods that only examine small, common variations in the
genome. The existing commercial availability of preconception testing
for recessive genetic conditions to individuals and couples who wish
to have children is also a potential area for expansion. Appli-
cation of WGS in this context can easily lead to the question of why
analysis should be limited to finding out about carrier risk status. If
removing filters is enough to obtain a WGA, the question is no longer
what we do, but what we do not want to know about ourselves.
Screening of newborns
Some advocates of the concept of tailor-made medicine suggest that
analysing personal genomes is best done as early as possible in life,
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namely at birth. Practically, this would entail expanding the current
neonatal heel prick screening based on WGS/WGA. Questions other
than those already listed regarding the balance between advantages and
disadvantages arise. The question is also whether analysing the com-
plete genome of a child without a medical indication is acceptable,
given all kinds of information about genetic characteristics will become
known that is only important far later in life. Don’t children have the
right to decide whether or not they wish to know about the strengths
and weaknesses in their own genome later in life? Current heel prick
screening does not pose this problem; it focuses solely on conditions
where timely treatment or prevention (often a diet) can prevent
significant health harm to the child. However, there is already a trend
towards expanding neonatal screening. According to the American
President’s Council on Bioethics (PCBE), the underlying interests –
particularly those of scientific research – are so great that the scenario
of genome-wide screening of newborns will be difficult to prevent.
Prenatal diagnostic testing and screening
It is now no longer a fantasy that the full genome could be sequenced
even earlier in life, namely during pregnancy. This would not be done
in the interests of personalised medicine, but within the context of
prenatal testing focused on allowing informed decisions about
whether or not to carry the pregnancy to term. If this is done based
on a possible health problem in the fetus, it is referred to as prenatal
diagnostic testing; a routine offer is referred to as prenatal screening.
Genome-wide diagnostic testing is already being used (using current
techniques) to help clarify unexplained ultrasound findings. However,
the scope of prenatal screening is also expected to be broadened.
Eventually, those who want as much information as possible about the
fetus will no longer be happy with anything less than the complete
genome. The question arises as to whether the primary goal of
prenatal screening will not be threatened. The broader the test, the
more diverse the potential outcomes, and the more difficult it will be
to enable the pregnant woman (and her partner) to provide true
informed consent. Will this not lead to almost every pregnancy
delivering a finding that forces the pregnant woman to decide on
whether or not to abort, even if it is only because of a finding whose
meaning is not yet clear? Finally, this scenario creates a new and
currently unaddressed problem: children born after whole-genome
diagnostic testing or screening already have a fully analysed genome.
The question remains whether or not this harms the right of the future
child to decide for him- or herself.
Screening of embryos
The introduction of increasingly broad testing also applies to the
screening of embryos created for an IVF treatment (pre-implantation
genetic screening, PGS). This involves the selection of embryos that
qualify for implantation into the uterus. Currently, this is conducted
largely based on morphological characteristics that appear to be
important for a chance at a successful implantation and pregnancy.
More informative tests that look at chromosomal abnormalities are
currently being developed. Certain experts believe that it will even-
tually be possible to conduct a genome-wide analysis on IVF embryos.
This seems to shift the goal of screening from selecting the embryo
that has the best chance of growing into a child, to selecting an
embryo that will grow into a child that is as good, or at least as healthy
as possible. If a choice must be made, is it not the responsibility of
doctors (and future parents) to choose the embryo with the best
health prospects? However, it would also mean that the entire genome
of an embryo that will potentially grow into a child has already been
charted. The question is whether this is acceptable.
Existing frameworks under pressure
The questions raised by the potential implementation of the thou-
sand-dollar genome are not all new. The scale of the challenges is,
however. More important is what is happening with the normative
frameworks normally used to define and answer such questions. They
are under pressure, starting to overlap or run into each other. This
applies primarily to the difference between diagnostic testing and
screening. If whole-genome sequence analysis is used to determine the
genetic background of a poorly understood health problem in an
individual patient, the motive remains diagnostic testing. However,
given the fact that at most a tiny amount of all health information
this delivers will have anything to do with the specific problem
being investigated, the procedure also closely resembles a form of
(undirected) screening. If this is the case, should such research not be
reviewed using the normative framework developed for screening?
A second issue is how analysing personal genomes without a
medical indication relates to the normative framework developed
for screening. Because it is impossible to grasp what predictive
information genome-wide, undirected screening may yield, it is
impossible to determine what the balance of advantages and dis-
advantages for the individuals to be tested will be. In the context of the
normative framework, it would appear not to be a good idea. But does
that framework provide the correct perspective for reviewing the
analysis of a personal genome? Reasoning from the ideal of persona-
lised medicine, everyone is a patient from cradle to grave. The
distinction between screening and patient care then loses all meaning.
Or maybe analysing the personal genome is an issue of the right of
individuals to obtain genetic information relating to themselves? The
discussion on this subject will inevitably receive a fresh impulse if a
market for sequencing and analysing personal genomes develops.
The distinction between reproductive and non-reproductive
screening is also becoming blurred. Until now, these were separate
worlds with their own normative frameworks and principles. For non-
reproductive screening, the emphasis is on health gains and a certain
amount of directiveness is not seen as problematic: it is fine to draw
people’s attention to their responsibility for their own health. Repro-
ductive screening, on the other hand, traditionally has a strong focus
on the highly personal character of reproductive decisions with
an ideal of professional non-directiveness. The application of gen-
ome-wide tests would lead to a blurring of the borders between these
two worlds, leading to difficulties in determining which normative
principles should guide decision making.
In conclusion, familiar normative frameworks appear to lose at least
part of their organising capacity and guiding character. Although
some of the developments discussed are problematic when viewed
from within these frameworks, there is also room to ask whether a
review or recalibration of these frameworks is necessary, should we
wish to continue providing guidance for the application of scientific
knowledge in healthcare.
Debate and new guidelines required
Further reflection on the developments outlined above and the
normative implications thereof for all parties involved, including
clinicians, scientists, jurists, ethicists, patient organisations and policy
makers, is of great importance. To begin with, there is a need for
guideline development by the professions involved in the application
of genome-wide diagnostic testing in adults, children and fetuses. The
most current question is how to responsibly deal with unsought for
findings of such diagnostic testing. Given the complexity of the matter,
in both normative and scientific terms, there is also a need for more
comprehensive reflection and debate.
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INTRODUCTION
In 2003, the first practically complete inventory was taken of the
building blocks of the human genome. Since then, scientists have
worked to develop a cheap method to quickly and reliably sequence
an individual’s entire genome. This has been called the ‘thousand-
dollar genome’.1,2 Following global efforts, success appears to be in
sight. This opens doors to a wealth of knowledge that will provide a
major impulse to scientific research into the meaning of the human
genome. This is also an important development for the healthcare
field: if it becomes possible to quickly and cheaply sequence
and analyse everyone’s ‘personal genome’, it clears a path towards
personalised medicine.
At the same time, it raises ethical, legal and social questions. Is
analysing an individual’s entire genome acceptable? Under what
circumstances and in what way? This monitoring report addresses
the issue. The goal is to outline the normative dimensions relating to
the thousand-dollar genome in broad strokes, thereby providing the
building blocks for the necessary debate on the acceptable and careful
implementation thereof.
Futures
The first goal of the ‘thousand-dollar genome’ is to obtain new
knowledge. Currently, knowledge about the functions of specific
fragments of the human genome and the meaning of variations
therein is still limited. However, if the complete genome becomes
available for a large number of individuals, comparisons can become a
powerful tool to gain better insights. As knowledge increases, the
‘thousand-dollar genome’ will become increasingly important to
healthcare. That is the secondary goal, which can for now only be
realised in part due to the still rudimentary knowledge.3,4 Once an
individual’s complete genome has been sequenced – meaning the
order of the chemical building block (base pairs) of the genome has
been determined – it can be fully or partially analysed. In this analysis,
the genomic variation found in that individual is compared with the
current knowledge about the meaning thereof. This creates a personal
genomic database that can subsequently be used to deliver prevention,
diagnostic testing and treatment to individual patients (personalised
medicine). This should make it easier to help individual patients
than is possible using current forms of care based on general
epidemiological data. Furthermore, it would make healthcare more
effective due to targeted interventions.
As with all major medical and social advances, it remains to be seen
what aspects of personalised medicine will be realised. A lot will
depend on the degree to which ‘genetic sensitivity’ will allow useful
risk and susceptibility profiles to be created for complex diseases
(caused by interaction between genetic and environmental factors)
and specific forms of therapy targeting such conditions.
Normative dimension
Even if that future will initially be only partially realised, we are facing
a development that raises ethical, legal and social questions that must
be addressed in a timely manner. Given the scope of the potential
social implications, the debate surrounding these issues is one that
affects more than just the professionals involved.
The discussion in this monitoring report limits itself to the
significance of the thousand-dollar genome to healthcare. This does
not take one away from the fact the debate deserves a broader
approach. Sequencing and analysing the complete genome of indivi-
duals will also yield information that may provide insights into certain
non-health-related traits, such as behaviour, cognition, ancestry and
personality. The questions raised by this overlap those relating to
information obtained about health. Both situations encompass sensi-
tive data that could lead to stigmatisation and discrimination. Appli-
cations outside the healthcare field also raise new questions, for
example, the advantages and disadvantages of using genetic infor-
mation to provide differential treatment for children in terms of
child-raising and education.
Structure of the report
The next section outlines the background of the ‘thousand-dollar
genome’. The sections from ‘Diagnostic testing’ to ‘Embryo screening’
discuss the potential applications thereof and potential related techno-
logies (WGS, WGA) within the context of medical diagnostic testing
and for various forms of screening. These sections also identify the
key normative questions raised. ‘Familiar frameworks under
pressure’ contains an inventory of the potential consequences of the
developments described for existing normative frameworks. The last
section lists the conclusions.
BACKGROUND
WGS is getting cheaper. This section provides a brief outline of the
implications of the availability of this technology for genome research
and healthcare.
The hunt for the ‘thousand-dollar genome’
With the completion of a first, practically complete inventory of the
human genome in 2003, a key goal of the Human Genome Project was
reached, leading to the formulation of new challenges for further
research.5 In September 2005, the Graig Venter Science Foundation
announced a 500 000-dollar prize for the first research group to
manage to sequence an individual’s entire genome for 1000 dollars
or less. The press release mentioned the major importance this
breakthrough could have for healthcare:
Once this threshold has been reached it will be feasible for the
majority of individuals to have their genome sequenced and
encoded as part of their medical record.
The as-yet unclaimed prize has since been brought under the
umbrella of the X-Prize Foundation. The prize money is now 10 million
dollars. This will go to the first research group capable of sequencing the
genome of 100 people with a high degree of reliability, within 10 days,
for no more than 10 000 dollars per genome. The Foundation website
links this objective with the promise of personalised medicine (targeted
prevention, effective therapy, better vaccines, lower costs), but under-
lines that cheap, fast and reliable sequencing is primarily important for
further research focused on unravelling the functional implications of
individual variations within the whole genome.
In addition to the cash prizes, a significant research grant from the
National Institutes of Health has led to strong competition between
research groups and the development of numerous next-generation
sequencing techniques. Some of these techniques aim specifically to
record individual genomes against the background of a known
reference genome. This path appears to be leading the way to the
thousand-dollar genome: in late 2009, researchers at the Californian
company Complete Genomics announced that they had successfully
managed to sequence the entire genome for three people with a high
degree of reliability for only about 5000 dollars in consumables.6
The falling costs of WGS in the past years now allows the genomes
of a larger number of people to be compared, allowing the genetic
variation between people (and groups) to be defined further.7 This
research is initially focused on the protein-coding part of the genome
(exome). This represents roughly one percent of the total, but is the
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part of the genome that appears to be most important for finding
associations with disease risks.
Significance of the ‘thousand-dollar genome’ for genome research
A subsequent step will allow researchers to further determine the
potential meaning of variations for disease risks and other phenotypic
differences between people. By comparing the genome of healthy
people to that of sick people, the variations contributing to specific
disease risks can be identified. This type of research is not new, but to
date has only been conducted using information obtained through less
detailed forms of whole-genome scanning.8 These studies primarily
examine variation at the level of single-base pair changes (single-
nucleotide polymorphisms, SNPs), small changes in the DNA that
may be associated with an increased risk of common diseases.9 Over
ten million common (occurring in more than 1 percent of the
population) SNPs have already been catalogued throughout the
genome. Another approach (which can be combined with this one)
looks at structural variations (insertions, deletions, copy-number
variations) within the whole genome.8,10
In just a few years, important discoveries have already been made by
genome-wide association studies (GWAS) using these techniques.4,11
However, not all (rare) disease-related variation can be tracked down
this way. Once WGS becomes affordable enough to be used for this
purpose, it will likely provide a significant further impulse to this
research.9
In order to clarify the contribution of genetic variation to the
development of disease and differences in disease expression, more
research is needed into the specific interaction between genetic and
environmental factors, as well as into the insufficiently well-under-
stood functional relationships between genetic factors (gene–gene
interaction). One example is the study initiated in late 2009 in the
United States into the as yet largely unknown genetic causes of
autism.12 To begin with, the exome (protein-coding part of the
genome) of all participants will be sequenced and analysed. The entire
genome of participants this does not yield any results for will be
sequenced. The researchers hope this will reveal regulatory genes in the
non-coding part of the DNA that influence gene expression, thereby
contributing to the development of autism. Without WGS, the
contribution of such genes is impossible to map systematically.
‘The thousand-dollar genome’ and the personalised medicine ideal
The expectations related to the availability of cheap WGS dovetail
nicely into attempts to personalise medicine. The most recently
published Biotechnology Trend Analysis (Netherlands) says the fol-
lowing on the subject:
The advantages of implementing the $1000 genome are legion.
Genetic screening or diagnostic testing will become cheaper
over time. With increasing knowledge about the genome and
the relationships between genes and the occurrence of a
condition, in part thanks to the use of bio banks, screening
via whole genome analysis may prove more valuable than the
current per gene analyses. The possibilities for prevention and
early treatment of diseases will increase, raising the average
health level. The expected patient response to treatment and
susceptibility to side-effects can be determined before treatment
is begun, and new health promoting strategies will become
possible. In short, the $1000 dollar genome – and more
generally X-omics research – allows for more tailored preven-
tion and treatment of disease (personalised medicine).13
It is essential to note that the personalised medicine described can only
be fully implemented in a ‘proactive’ model of healthcare, where one
does not wait for people to exhibit disease symptoms, but health risks are
mapped out while they are still healthy.4 A health risk assessment to be
carried out for everyone, recorded and kept up-to-date in an electronic
patient file should allow various forms of information to come together
in the form of risk profiles: questionnaire information about environ-
mental factors and lifestyle, outcomes of psychological testing, family
health history, findings of imaging tests and genomic information, both
at a DNA level (stable genomics) and in terms of gene expression and
protein and metabolic profiles (biomarkers).
The goal becomes the provision of preventive, diagnostic and ther-
apeutic interventions across the entire continuum of health to sickness in
a personalised manner based on the person’s individual risk profile.4 For
healthy individuals: lifestyle recommendations and other forms of
prevention; for people with health complaints: targeted diagnostic testing
focussing on specific subtypes of conditions; for sick people: medication
and other forms of therapy selected on the basis of predicted response
(personalised medication, pharmacogenetics).
Currently, only the first careful steps have been taken towards making
this vision of the future a reality. In the past few years, important
breakthroughs have been made in the implementation of genetic
susceptibility profiles in the prognosis and differentiated treatment of
cancer.4 When it comes to the prevention of common diseases, the added
value of genetic risk profiling remains largely hypothetical.14 Although
GWAS research has identified genetic risk factors for a number of
common diseases, far from all relevant risk-increasing and -decreasing
factors for such conditions have so far been mapped out. Genetic
susceptibility tests based on currently known variants are therefore not
able to reliably differentiate between individuals who do or do not have
a significantly greater or lower risk of disease. Offering such testing is
therefore premature.14–17 Secondly, for most of the conditions in
question (as shown in studies with identical twins), environmental
factors have a far stronger influence on disease risk than genetic factors.
The predictive value of genetic factor-based risk profiling will therefore
only be minimal in most cases.18 Only for conditions where genetic
factors play a larger role in determining disease risk is this likely to be
different. The promising results for a number of specific conditions
(including age-related macular degeneration and Crohn’s disease) fall
into this category.14 Thirdly: insofar as genetic risk profiling adds
anything to prediction based on environmental factors, the clinical
usefulness of the additional information depends on whether it will
make the individuals involved more inclined to modify their lifestyle.
This is far from certain.19
In summary, it remains extremely unclear if and when the promise
of the personalised medicine ideal will be realised. The availability of
the ‘thousand-dollar genome’, the ability to cheaply sequence complete
genomes for individuals, is primarily important for the research into
the complex relationship between genetic variation, environmental
factors and health. Some commentators expect that in the future, this
will lead to – as part of individualised health risk profiling –
standardised WGS and analysis for each individual. When speaking
of WGA, this report refers to the interpretation of the ‘raw data’
obtained by sequencing in the light of current knowledge on its
meaning for the individual’s health prospects.
The previously described scenario (routine analysis of the entire
genome) is addressed in the sections ‘Screening of adults’ and
‘Screening of newborns’ of this report. The next section will first
examine a near-future application of the thousand-dollar genome in
healthcare: WGS with the goal of diagnosing disease for which the
genetic background is not (or insufficiently well) understood.
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DIAGNOSTIC TESTING
Sequencing the whole genome is expected to play a role in healthcare
in the short term, specifically in the diagnosis of diseases for which the
genetic background is not or insufficiently understood. This section
will first briefly outline the background of this application. Next, it will
discuss a number of difficult questions raised by the fact that genome-
wide diagnostic testing inevitably means far more genetic information
about the patient is revealed than is necessary for answering his or her
request for help.
Genetic diagnostic testing using arrays
Using micro arrays (DNA chips), it is currently already possible to
perform directed analyses of selected sections of the patient’s genome
for diagnosis or prognosis based on relevant types of genetic variation
(gene expression, structural variation and mutations of SNPs).20 Such
an array can, for example, be designed to specifically look for genetic
factors known to play a role in the development of hereditary heart
disease and the successful treatment thereof.21,22 This kind of ‘cardio-
chip’ is expected to provide faster, more accurate diagnostic testing for
patients with symptoms, a better test for tracking down asymptomatic
carriers (early diagnosis, for example, in athletes) and allow better
justification of treatment strategies based on individual prognostic
profiles.
Such a targeted approach is only possible if one knows in what
groups of genes to look for the cause of the complaint or medical
problem. This is not always the case. For example, the patient might be
a child with a mental retardation with an unknown cause, or a patient
with a rare neurological condition, unknown forms of cancer, and so
on.23 ‘Genome-wide’ arrays have recently been deployed for such
cases, for example, an array CGH, which allows the entire genome to
be searched for structural variations (such as gene deletions or
duplications) that may explain the condition.24 In 30% of cases in
which an array was performed on the child, testing the parental
genomes is also required to interpret the results.
Genetic diagnostic testing using WGS
If costs are no longer a barrier, it is easy to imagine that every patient
who requires genetic testing will undergo full-genome (or to begin with
the coding part of it: exome) sequencing. WGS simply means making
the entire genome accessible for diagnostic analysis at a single-base
pair level. WGS provides ‘raw data’ (a library of three billion letter
combinations) that means nothing without additional analysis. This
analysis is conducted using software that reflects the (still limited)
current understanding of the meaning of the variation found in the
genome. Filters can be used to ensure as much as possible that only
information relevant to the diagnosis of a specific health problem
becomes available (targeted analysis). However, if it is unclear which
genes need to be examined (for example, in the previously noted
situations in which genome-wide searches are already being conducted),
a full analysis of the data obtained via WGS is the obvious choice: WGA.
Unsought for findings as a complication of genome-wide diagnostic
testing
Genome-wide diagnostic testing (currently still based on array techno-
logy, soon possible using WGS/WGA) does not look for specific ab-
normalities in certain parts of the genome in a targeted fashion, but
searches the entire genome for the possible cause of an unexplained
problem. It is inevitable that in addition to the sought information,
unsought for information about known health risks will be revealed,
as well as findings for which the meaning remains unclear. Currently,
the latter applies to most findings of genome-wide diagnostic testing.
Unsought for, clinically relevant findings can have both positive and
negative consequences for the parties involved (the examined indivi-
dual, his or her parents, other blood relatives). If this concerns a
predisposition for a condition that is preventable or treatable if detected
in time, or information about carrier status of recessive conditions that
affect (future) reproductive choices, the party involved will often see
this as valuable new knowledge. This is likely also true for information
on health risks that can be minimised through lifestyle changes.
However, the situation is often different when it comes to untreatable
conditions. Such information can have negative social and psycho-
logical effects for the involved parties. This could include problems in
obtaining certain forms of insurance or getting or keeping jobs.
A number of recent publications have explicitly mentioned
unsought for findings in genome-wide diagnostic testing and pointed
out the challenge this presents for daily practice. The cases described
related to genome-wide array CGH in children with unexplained
mental retardation. In one case, a rare de novo (meaning: not inherited
from the parents) gene deletion was found that leads to a very high
risk of Li-Fraumeni syndrome.25 This is a hereditary form of cancer
that often occurs early in life, presenting with tumours in multiple
organs. There is no effective treatment for Li-Fraumeni syndrome. In
another case, carrier status for an early-onset form of Parkinson was
detected.26 Because the latter condition is recessive, this was not an
additional disease burden for the child (other than a potentially higher
risk of the late-onset form of Parkinson’s disease27). However, the
finding did lead to further genetic testing of the parents due to their
wish to have more children. There was a small, but not negligible
chance that the father or the mother had two abnormal alleles of the
gene in question (Parkin). Such a result would predict that the parent
in question would actually start developing symptoms of Parkinson’s
disease around the age of 40.26
Unsought for findings in diagnostic testing are nothing new in
medicine (consider imaging techniques, for example). Targeted forms
of diagnostic testing can also lead to unsought for information coming
to light, potentially in relation to the disease or cause of disease that
was the reason for initial testing. Genome-wide analysis does greatly
increase the odds of such findings. It is already dubious to label
findings of genome-wide diagnostic testing using current techniques
as ‘chance findings’ or ‘unexpected findings’; once all sequences within
the genome are analysed, the position becomes essentially untenable.
It is clear in advance that all genetic information available based on the
current state of knowledge, health-related and not, will be obtained,
along with a large number of as yet not fully understood findings. All
findings that are clinically relevant or otherwise potentially important
to the parties involved will in principle have to be shared with them.
Therefore, the consequences that obtaining this information will have
for the parties involved cannot be left unexamined if such a far-
reaching test is to be justified. That these findings are unsought, and
therefore a ‘by-product’ of diagnostic testing performed on indication,
is not a reason to view them differently.
In practice, attempts will be made to limit the problem of unsought
for information by using targeted analysis (filters) wherever possible.
However, if the location of the cause of the problem on the genome is
unknown, a broad approach will be desirable. In theory, certain
information considered undesirable can be filtered out, but the
more filters are used, the greater the odds that testing does not lead
to a diagnosis.
Informed consent and the right not to know
Diagnostic testing and screening require the patient’s informed con-
sent. The care provider must give the patient the information he or she
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needs to make a personal and reasoned decision about the proposed
treatment or testing. For genome-wide diagnostic testing, the fact that
the test may lead to unsought for findings must be discussed and the
patient must be informed of the potential consequences. Only then
can he or she (or the parents on behalf of their child) make a well-
informed decision about the proposed tests. Do the health benefits
associated with the test outweigh the odds of learning about damaging
or otherwise disadvantageous health information? Particularly where
WGA is concerned, the question arises whether approaching the issue
via the classic informed consent model is realistic. Can care providers
themselves maintain a grasp of the potential outcomes of genome-
wide diagnostic testing and the chances and implications thereof?
Insofar as they can, do they have the time and the means to present
this information to the person in question in an understandable
fashion? Won’t the amount and variety of the information, as well as
the fact that a great deal remains unclear or uncertain, preclude a well-
informed choice?
The patient may wish to be informed about some unsought for
findings, but not about all of them. For example, he might want to
know about findings that indicate health risks that can be mitigated
through timely treatment or lifestyle changes, but not about predis-
positions for severe conditions that cannot be treated or prevented.
Recognition of both the right to know and the right not to know
means that people should be given the opportunity to make such
choices in advance.28 Precisely how this should be given form is less
clear. Discussing all possible findings in detail in terms of nature,
severity and treatability is unrealistic. At most, a form of generic
consent might be obtained,29 where individuals can indicate the type
of findings they do and do not wish to be informed of based on a
number of general multiple choice questions. This approach is
advocated in the previously mentioned publications on genome-
wide array CGH in children with unexplained mental retardation.
The authors propose asking patients, or parents of a child to be tested,
prior to genome-wide diagnostic testing
whether (y) they wish to be informed about any additional
genetic findings (without direct connection to the phenotype in
question) with predictive value for the health of the proband
and potentially her/his family; (whether) they only wish to be
informed about such additional genetic findings if effective
treatment options or surveillance programmes are available;
(and also whether) they wish to be informed about a carrier
status for an autosomal recessive disease – that is, about a
condition which may have implications for reproductive deci-
sions of the proband and/or family members.26
These formulations immediately raise a number of questions. To
begin with, what the starting point should be: to inform or not? The
authors appear to assume that clinically relevant additional findings
unrelated to the initial problem should not be shared unless the party
in question has indicated they do want to know. But isn’t the opposite
also, and possibly even more defensible? Secondly, the choice about
what the involved parties wish to know is limited to: ‘findings (y)
with predictive value for the health of the proband and (y) her/his
family’. The final sentence, concerning carrier status for an autosomal
recessive disease, can be seen as an exception to the limitation to
health information. But is the limitation as such defensible? Should
not the right to know encompass all genetic information that the
involved party himself feels is useful, even if it does not apply to his
health prospects? Thirdly: shouldn’t the second sentence (addressing
the delimitation of information that may contribute to actual health
gains) not also address the importance of timely detection, the
potential severity of the condition, and the stage of life in which
initial symptoms may occur? Or does this immediately make every-
thing too complicated, and does so much then need to be discussed
and explained that little remains of the entire concept of generic
consent? Fourthly, the question arises of whether doctors can fulfil
their responsibilities for a child given into their care if parents pre-
emptively indicate that they do not wish to know about additional,
unsought findings of genome-wide diagnostic testing that may have
significant effects on the child’s health. Conversely, there is also the
question of whether parents have the right to (health) information
about their child that may only become relevant to him or her later in
life. Does this not rob the child (if it is not immediately clear that it
will never be competent) of the possibility to later decide whether it
wants to know or not know?28 Finally, do formulations that refer to
the interests of the child and of his or her relatives in a single breath
not encompass too much potential conflict? Can the potential inter-
ests of relatives be a reason to limit the child’s right to not know?
These questions emphasise that the notion of ‘consent’ (let the
patient or his representative decide what he does and does not want to
know) does not provide a simple solution to the complication of
unsought for findings of genome-wide diagnostic testing, particularly
where the interests of children are involved.
Inform or withhold?
Clinically relevant information obtained through diagnostic testing
must be shared with the patient (or his representatives), unless they
have stated they do not wish to know. In principle, the same applies to
unsought for findings that may be important for a patient’s health
prospects. This duty to inform is not absolute, however: under certain
exceptional circumstances, the care provider may withhold health
information because there is good reason for the worry that said
information could severely harm the patient (therapeutic exception).
The implementation of genome-wide diagnostic testing may lead to
situations that raise such issues. Should the finding – unrelated to the
original testing reason – that a girl runs a very high risk of developing
breast cancer be shared? For minors, in addition to potential harm
(psychosocial, social) it is also important to remember that sharing such
information may violate future autonomy, unless of course there is such
a severe mental handicap that it is clear the child will never be capable
of making autonomous choices. The prevailing consensus in the debate
on predictive testing of children for severe late-onset diseases remains
that such testing is not permitted unless treatment or prevention that
must be initiated during childhood is possible.30 What does this entail
for the acceptability of sharing unsought for information with the same
implications? Does it make a difference that the information is already
available? Furthermore, the information may also be of great impor-
tance to parents or other blood relatives, either in terms of their own
health prospective or in relation to reproductive choices. Imagine
genome-wide diagnostic testing reveals a child runs a very high risk
of developing hereditary breast cancer later in life. The information is
not relevant to her at this time, and has the potential to be harmful.
Is withholding the information until adulthood a realistic option?
Does the right of the child to not yet know prevail over the current
importance for the health of mother and aunts?
In addition to desired and unsought for information, genome-wide
diagnostic testing mostly yields data for which the clinical significance
is as yet unclear. What can be considered useful information, and what
part of it is noise to be withheld? The scientific research mentioned in
the previous section will lead to fleshing out more and more know-
ledge gaps in the years to come. Part of what is currently noise will
prove to be meaningful information.
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Storage of genetic data
Another issue is what should happen with all of the (largely unsought)
information generated by the implementation of WGS and WGA in
clinical genetic practice. A differentiation must be made between the
raw data, which is the product of sequencing (WGS), and the
outcomes of the sequencing analysis (WGA).
The raw data can be stored (in the patient file) for future analysis.
Should additional genetic testing be necessary later in the patient’s life,
the data will not need to be generated again. This assumes the costs of
storing the data do not outweigh those of new sequencing, and that
newer sequencing will not be more sensitive or better than current
techniques. Costs include not only the permanent physical storage of
the data, but also securing it. Although the raw data obtained through
sequencing has no meaning, anyone with the correct software can
theoretically perform the analysis. Therefore, the raw data must also be
considered and treated as privacy-sensitive data.
Genetic data obtained through sequence analysis will need to be
stored in the patient file, at least insofar as data relevant to the patient’s
(or their relatives’) health prospects are concerned. This raises the
question of what should happen with genetic information that has been
obtained, but is not desired by the patient and has therefore not been
shared with him. How can this information be stored in such a way that
the patient is not unwittingly confronted with it? Is it not better to
destroy the said information? Is this allowed, or perhaps even manda-
tory? Can this problem be solved by asking the patient in question what
should happen with the data he or she does not wish to know about
during pre-test counselling? What about the data obtained about a child
that may be important in his or her later life (including reproductive
decisions)? Another question is what should happen with findings with
unclear meanings, or that do not appear relevant for health prospects.
Do they belong in the medical file, as the future may tell whether they
do have health-related relevance? Undoubtedly, the implementation of
genome-wide diagnostic testing will lead to new debate about how long
these data must be stored in the medical file.31
‘The thousand-dollar genome’ and the role of the doctor
Within the field of medicine, the debate is ongoing regarding the extent
to which doctors can be expected to contact patients treated (or
counselled) in the past if new scientific insights make improved
diagnostic testing or prognostics possible for the condition the patient
was treated for.32,33 On the one hand, it seems only natural to do so if
the involved party may expect health gains, or at the very least greater
insight into his medical condition. After all, wasn’t that the original
reason for seeking out medical aid? On the other hand, it is uncertain
that the party in question actually wants to receive the new infor-
mation, with all that implies, even if it might potentially lead to health
gains. Where legally incompetent people are concerned, the question
that counts is whether renewed contact is truly in the best interest of the
party in question. Hunter et al’s warning appears justified: ‘the uninvited
recontacting of patients includes significant risk of causing harm’.33
The legal aspects are also far from simple. As long as there is an
ongoing doctor–patient relationship (this applies to the GP, but
possibly also to specialists if there are regular check-ups), there is a
clear framework within which the doctor may be expected to inform
the patient about new, relevant insights (wherever possible taking into
account his or her explicit desire not to receive certain types of
information). But does this responsibility extend beyond that? To what
degree is it part of the aftercare that may be expected of a good care
provider? And is it only about gaining new insights within the context
of the original request for help, or does this responsibility also extend
to other aspects of health?
The introduction of genome-wide diagnostic testing makes these
questions all the more urgent. New scientific insights into the meaning
of certain genome sequences may cause test results recorded in a
patient’s medical file to be viewed in a new light. Data that initially
appeared not to have any clinical relevance are suddenly important to
the patient’s health. Can part of the problem be solved by asking
patients when entering into a treatment relationship whether and
under what conditions they would like to be contacted again if new
scientific insights warrant it after the end of the said relationship? This
is also not without problems: ‘this does not take account of the matter
that the patient cannot foresee the future and the possible impact that
new information could have, or that their perspective may change
with time’.33 Furthermore, there is the question of what active and
systematic implementation of a broadly implemented duty to recon-
tact would entail for the burden placed on care providers and the
organisation of healthcare. Would it not be preferable, so some
have proposed, to advise patients to take the initiative after a few
years to ask whether new knowledge has been obtained that may be
relevant to them?
The above concerns recontacting after termination of the treatment
relationship. However, this does not answer the question within the
context of an existing doctor–patient relationship: what do all the
unsought for and non-care question-related outcomes of WGA mean
for the scope of a doctor’s responsibility? This is also not an entirely
new question. The previous monitoring report from the Dutch Centre
of Ethics & Health (CEG) on screening in general practice pointed
towards a possible shift in the GP’s/doctor’s task conception: from a
solely complaint-oriented care provider to a ‘health monitor’ who also
advises patients on all possible aspects of health on his own
initiative.34 The introduction of the thousand-dollar genome raises
the same questions about the role of the doctor and the nature of
the doctor–patient relationship. If the medical file contains all of the
results of WGS and WGA (performed within the context of medical
diagnostic testing), is it up to the doctor to inform the patient if new
knowledge is obtained about the health implications of that data, even
if it has nothing to do with the original reason for the test? And how
should cooperation be organised and responsibilities be shared
between GPs and specialists?
SCREENING OF ADULTS
The thousand-dollar genome not only opens possibilities for
diagnostic testing, it also brings genome-wide screening closer to
becoming a reality. Some advocates of the personalised medicine ideal
believe it would be wise to analyse the genome of every individual in a
systematic and active manner. After all, these data are an important
precondition for preventative and curative medicine tailored to
personal health needs. As this would entail (systematically) offering
(genome-wide) medical testing without a cause in the form of
complaints or a family history of disease, this is not diagnostic testing,
but screening.16,35 This section discusses the implications of genome-
wide screening of adults.
Genome-wide screening and use of filters
As is the case within the context of diagnostic testing, the distinction
between sequencing and analysis is also important here. Sequencing
the entire genome (WGS) may, but need not mean that all raw data
are also analysed (WGA). Using filters allows partial analysis to be
performed: this technique examines certain parts of the genome while
leaving the rest of the raw data unanalysed. After full or partial
analysis, the raw data (the sequenced genome) can remain available
for further analysis should it be necessary at any point in the future.
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If sequencing were to become so cheap in the future that careful
storage of the data is more expensive than generating it anew, it is
likely the data will be destroyed after each use.
Use of filters allows the implementation of WGS as the basis for
targeted genetic screening. If screening for a specific disease or
susceptibility requires searching for multiple mutations, sequencing
the entire genome may prove to be a cheaper solution than using
individual tests. Filters can be used to prevent uncovering unsought
information wherever possible. The fact this is not always possible is
no different from current forms of targeted genetic screening. How
these filters should be fine-tuned in daily practice (for both diagnostic
testing and screening) will remain a complex issue: a test with a
broader scope may be more informative, but may also yield more
difficult to deal with unsought information.
For genome-wide screening with the purpose of analysing personal
genomes, it is imaginable that filters will be used to filter out certain
predictive information not wanted by the party in question. This
could include predispositions for untreatable late-onset diseases,
genetic sensitivity to psychiatric conditions, or other outcomes
that may represent a major burden and could have negative social
consequences.
Analysing the personal genome
As a proof of principle, American physicians and researchers recently
published about sequencing and analysing the ‘personal genome’ of a
40-year-old man. He had a family history of cardiovascular disease
and early sudden death, but no complaints of symptoms himself.36
The analysis focussed on clinically relevant genetic variation: predis-
positions for monogenetic diseases, and lesser or greater genetic
sensitivity to common conditions and variants that influence indivi-
dual response to medication. The outcomes included rare variants in
genes associated with sudden cardiac death and an increased sensi-
tivity to having a heart attack (no surprise, given the family history),
but also gene mutations associated with diseases not present in his
family history, carrier status for recessive conditions, pharmacogenetic
information and information about greater or lesser odds of common
diseases, with higher post-test scores for conditions including cardio-
vascular disease, obesity and type 2 diabetes. The goal of the exercise
was to demonstrate that analysing personal genomes can yield
clinically relevant information.36
In the (currently hypothetical) scenario in which the ideal of
personalised medicine is so well developed that analysing personal
genomes could make a valuable contribution to individual personal
health management, the question of optimal timing arises. The earlier
the information is obtained, the greater its potential value for the
individual and for healthcare. Two possible points in time are men-
tioned in the debate: as early in life as possible, meaning at birth (see
the next section for more) or upon reaching legal age.37,38 In the latter
case, the individual can decide for himself whether or not to take part
in this form of screening, while it is still early enough in life for
potential benefits to be significant. Potential benefits not only include
using the information obtained for personalised lifestyle recommen-
dations, prevention and interventions during the course of the
individual’s life, but also the potential value of the information for
the reproductive decisions that many young adults will have to make.
In addition to the potential advantages of analysing personal
genomes, there are also all too real disadvantages to obtaining
information that could be a burden or even harmful. Here too, filters
could be used to decrease the odds of obtaining unwanted informa-
tion. What does need to be considered is that the exact meaning of
genetic variation is currently largely unknown and that the use of
filters is based on current levels of knowledge. What appears to be
innocent noise now may prove to be meaningful later. Disadvantages
also include worry caused by (still) unclear outcomes, as well as the
subsequent – often unnecessary – contacts with healthcare (coun-
selling, further testing and treatment). As long as there is no clear
positive balance of advantages and disadvantages, there can be no
responsible implementation of genome-wide population screening
within public healthcare (see the section ‘Genome-wide screening in
the context of the existing normative framework’). However, it is likely
that commercial providers will see a market for this kind of testing
before then. In effect, the market already exists, albeit currently only
implementing less advanced (and therefore much cheaper) tests that
only examine small, common variations in the genome.
In his recent book The Language of Life, Francis Collins (director of
the American National Institutes of Health, former director of the
National Human Genome Research Institute) describes his experience
with such tests. Collins had his genome tested by three different
commercial outfits: deCODE, 23andMe and Navigenics. The labora-
tory tests he received in return (after submitting physical samples)
were largely the same, but the interpretations included (in terms of
higher or lower risk of developing certain common conditions, or a
greater or lesser sensitivity to certain commonly used medicines)
displayed differences reflecting the ‘immature state of making predic-
tions from these DNA results’.39
However, Collins does believe these are the beginnings of a positive
revolution in how we address health: ‘learning your DNA secrets can
be the best strategy for protecting your health and your life’.39 People
who know (like Collins) that they have a slightly elevated risk of type 2
diabetes will be more motivated to listen to lifestyle recommendations
or exercise more, for example. Whether this actually works (and if so,
under what circumstances, and for whom) is a question that requires
further research to answer.19 Regardless, according to Collins, fully
sequencing and analysing personal genomes will be the next step in
the development, and one we can expect soon:
The analysis I had done tested one million places in my DNA.
But this is just the beginning. Soon, probably within the next
five or seven years, each of us will have the opportunity to have
our complete DNA sequenced, all the three billion letters of the
code, at a cost of less than $1000. This information will be very
complex and powerful. Careful analysis of the complete content
of your genome will allow a considerably more useful estimate
of your future risks of illness than is currently possible, enabling
a personalized plan of preventive medicine to be established.39
Preconception carrier status screening
In the scenario outlined by Collins, it would be wise not to wait until
middle age has passed (as it had in his case) to have one’s personal
genome analysed, not only because personal prevention is best
initiated early, but also because in addition to information that can
affect one’s own health, information will also be obtained about
diseases not affecting oneself personally, but that may be passed
down to offspring. This relates to (sex-linked or autosomal) recessively
inherited disorders. Most people who are (healthy) carriers of such
diseases are not aware of it, so having a child with the disorder in
question comes as a complete surprise. Autosomal recessive conditions
only lead to disease if both man and woman are carriers of the
condition. In such cases, the odds of having a child with the disease
are 1 in 4. People who know this in advance can take this into account
when making reproductive choices. In addition to deciding not to
have (genetically related) children, options include prenatal diagnostic
testing with the possibility of abortion if the fetus has inherited the
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disease gene from both parents, or reproduction via in vitro fertili-
sation (IVF) combined with embryo selection (pre-implantation
genetic diagnosis (PGD)) focused on ensuring any children born do
not have the disease.
Of course, it is unnecessary to analyse the entire genome in order to
test for carrier status for recessive, inherited diseases. At this point in
time, it is far more logical to implement targeted preconception carrier
status screening for relevant mutations.40–42 The Health Council of the
Netherlands, among others, has recommended examining whether such
screening can be offered to people of reproductive age. This screening
should allow tracking down or ruling out carrier status in the popula-
tion for common autosomal recessive diseases such as cystic fibrosis and
haemoglobinopathies.42,43 New techniques, such as the use of DNA
chips and sequencing, will allow carrier status to be determined for
many more recessive conditions than have been the topic of discussion
until now, without significantly increasing the costs. A Californian
company recently introduced a ‘universal’ (meaning: not only suitable
for a subpopulation) carrier status test that can identify carrier status for
over one hundred rare, recessively inherited conditions using a single
test.44 An individual test costs 350 dollars, and is (partially) covered by
some American health insurance companies.
Critics have pointed out that it remains to be seen how reliable the
test is in identifying all of these conditions.45 False-positive results may
cause unnecessary worry and testing, along with the associated
burden, risks and costs thereof, as well as lead to unnecessary decisions
not to reproduce or have a genetically related child. Furthermore,
the message that this is a ‘universal test’ could easily lead to the
misconception that normal results guarantee healthy children. The fact
there are many more rare, recessive conditions than the hundred
targeted by this test alone means one should be wary of unwarranted
reassurance. However, this does not invalidate the usefulness of a
broad, preconception carrier status test, as long as it is of good quality
and offered in a well thought-out manner.
From a genome-wide test for carrier status risks to a personal
genome?
It can also be expected that the offerings of the company mentioned
above is only a first step towards further expansion. At a poster
presented during the conference of the American Society of Human
Genetics in November 2010, American researchers from the National
Center for Genome Resources announced they were working on a next
generation sequencing-based test for carrier status for more than 400
recessive, inherited conditions, to be offered to couples wanting to
have children.46 Individuals wanting to compare their full risk of
transmitting recessive conditions to a potentially corresponding risk
profile in their partner will ultimately not be satisfied with anything
less than mutation analysis of the entire genome. In his above-
mentioned book, Collins writes:
Debates about the appropriateness of carrier screening will be
likely to change in the coming few years, as more and more
individuals will have complete DNA sequences of their entire
genome determined, revealing all of their carrier status risks
and providing an opportunity for couples to know about those
risks prior to initiating a pregnancy. It is likely that within a few
decades people will look back on our current circumstances
with disbelief that we screened for so few conditions.39
If WGS becomes a cheap and therefore obvious choice for charting
‘all carrier status risks’ in the near future, this means filters will be
required to limit the analysis to these carrier risks. However, in the
scenario described by Collins, the question arises of why one would do
this. The filters need only be left out to move from a genome-wide
carrier status test to analysing the entire genome. Of course, this
would be a major step with far-reaching consequences, due to the far
greater complexity of the genetic information that will be obtained.
Not everyone is as convinced as Collins that analysing entire genomes
will be of overall benefit to the individuals involved or to society. As
long as the advantages are uncertain, and the potential disadvantages
loom large, it appears wise not to take this step. However, if the only
thing necessary to implement it is removing filters, the debate on the
advantages and disadvantages of personal genomes is placed in a new
light. The question then becomes not what we do want to know about
ourselves, but what we do not.
SCREENING OF NEWBORNS
In the debate on the contribution personal genomes may make to the
ideal of personalised medicine, there are also voices calling for analys-
ing the personal genomes of newborns. In addition to the questions
raised in the previous section, this also leads to a new potential
problem: how does this relate to the right to self-determination?
Genome-wide screening of newborns: a good idea?
Some commentators believe it is wise to sequence and analyse an
individual’s entire genome at the very beginning of his life, as part of
the existing heel prick screening of newborns. This makes genetic
information available from birth that can be used to deliver persona-
lised disease prevention and health promotion initiatives. A British
government report presented the idea as follows:
One long term possibility that has been suggested is to screen
babies at birth as part of the standard postnatal checks and to
produce a comprehensive map of their key genetic markers, or
even their entire genome. Major investment is currently being
made in information technology in the NHS (National Health
Service), including the development of an electronic patient
record for each person. The baby’s genetic information could be
securely stored on their electronic patient record for future use.
It could then be used throughout their lifetime to tailor
prevention and treatment regimes to their needs as further
knowledge becomes available about how our genes affect our
risk of disease and our response to medicines.47
According to the previously referenced book by Collins, it is ‘almost
certain’ that complete sequencing will become part of neonatal
screening in the next few years:
(y) as we learn more about effective interventions for genetic
risk factors, and recognize that interventions early in life
provide significant advantages, it will become more and more
compelling to determine this information at birth.39
Upon the request of the British government, the Human Genetics
Commission has examined this idea. In its report (Profiling the
Newborn: A Prospective Gene Technology?) the committee concludes
to reject the idea. No matter the exact balance of advantages and
disadvantages – depending largely on the realisation of the ideal of
personalised medicine – analysing a newborn’s complete genome
violates the principle of respecting autonomy.38 After all, such
screening will reveal all kinds of findings that are of no importance
to the child’s immediate health, but may have serious conse-
quences for his or her later life. By actively looking for such information
unasked, the child may not only be harmed, but he or she will also be
robbed of the choice to decide for him/herself, later in life, as an adult,
about what he/she wants to know about his or her genome.
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That the child cannot consent to being tested does not stand in the
way of current heel prick screening, because it is focussed on treatable
conditions of early childhood. Analysing the entire genome, however, will
inevitably lead to obtaining predictive information about potential health
problems that are only expected later in life. This may include informa-
tion about an increased genetic sensitivity to common (multifactorial)
diseases (such as diabetes or cardiovascular disease). But it can also reveal
carrier status for monogenetic abnormalities that can lead to disease later
in life, including severe conditions such as hereditary breast or ovarian
cancer, Huntington’s disease or the hereditary form of Alzheimer’s
disease. The prospect of developing such a disease (or awareness of
a high risk of doing so) is a burden that could harm the child’s
psychosocial development. Furthermore, this information, which cannot
always be concealed, could lead to difficulties obtaining some insurance
cover and potentially to discrimination in the employment market.
There is a broadly shared (but not universal) consensus that
children may not be tested for carrier status of diseases that only
manifest in adults, unless there are treatment options or forms of
prevention that must be initiated in childhood in order to significantly
change the course of the disease.28,30,38 In the absence of such
interventions, the child will primarily experience the negative effects
of a positive (unfavourable) test result. Furthermore: once the infor-
mation is out there, he or she can no longer choose whether or not to
know later in life. This violates what Feinberg calls the child’s
anticipatory autonomy rights.48 The child cannot exercise his or her
right to self-determination yet, but others can still make decisions now
that retain or violate his or her future rights. Within this context,
Feinberg refers to the child’s right to ‘an open future’.
Criticism of this approach has come from authors who emphasise it
can also be in the child’s best interest to grow up being fully aware of
the carrier status of severe late-onset conditions.49 By emphasising this
aspect, they put the autonomy argument into perspective. Most
authors do not support this viewpoint. Regardless, this debate relates
to genetic testing requested by worried parents from families with a
history of disease. This is a completely different context from screen-
ing, in which the party in question may obtain unexpected informa-
tion about severe late-onset conditions.
It must also be considered that the information available through
genome-wide analysis affects not only the child’s (future) health, but
also all manner of other traits partially affected by genetic factors, such
as behaviour, personality and cognition.39,50 These are all extremely
complex properties for which little is currently known about the
genetic component. The danger exists that incomplete knowledge
about potentially relevant genetic characteristics will still be used by
parents when making child-raising choices. The question remains
whether this is in the child’s best interest. A real worry is that
overvaluation of the genetic factor will pre-emptively limit the child’s
room to develop differently from how parents fear or wish. The ‘right
to an open future’ is endangered here as well. In the meantime,
commercial parties are already addressing potential interest in parents.
For example, the website ‘mygenes-mychild’ advertises testing children
for genes that could play a role in the development of behavioural
problems without second thought:
Obtaining a child’s genetic information through genetic testing
can possibly help parents know what to expect. The gene
variant that scientists look for is the one that allows children
to learn from their mistakes. About 30 percent of people lack
that capability, genomic scientists now say. This information
can prepare you to raise your child. (http://www.mygenes-
mychild.com/articles/childs-genetic-information/index.php).
The idea of holding back certain information (not to share it with
the parents but store it nonetheless) until such time as the child is
capable of deciding what he or she does or does not want to know39
does not solve the problem. How does one prevent the child receiving
the information without wanting to? And is it possible to enable the
child to do something with the information without impinging on his
or her right to not know? It appears more useful to pre-emptively use
filters to prevent information from becoming available that has no
advantages for the child but does have potential disadvantages, and
that also rob him or her of the possibility to later decide what he or
she wants to know about his or her personal genetic makeup. This
does raise the question of what then remains of the concept of
analysing the entire genome at birth. If the filters are applied strictly,
this will result in a form of screening that does not differ significantly
from the current heel prick.
Genome-wide screening of newborns: an inevitable development?
The PCBE, however, noted an irresistible trend towards the increas-
ingly broad screening of newborns.51 The PCBE is no less critical of
such practices than the British report referenced above, with the
important difference that they do not see genome-wide neonatal
screening as a hypothetical scenario, but as an inevitable endpoint
of an ongoing development that is being guided by a number of
factors that strengthen each other. The logic of personalised medicine
is primary among these:
Once personalized genomic medicine becomes standard medi-
cal practice for adults, the logic of providing physicians with
this powerful tool earlier and earlier in the patient’s life may
prove inescapable. Even if cancers, for example, are relatively
rare in children and adolescents, why wait until adulthood to
uncover susceptibilities and vulnerabilities that could well be
countered by changes in diet and life habits (to say nothing of
prophylactic therapies) at an early age?51
The PCBE sees the further development of the research importance
of this concept (personalised medicine) as a second factor driving
broadening of neonatal screening:
An obscure illness for which there is as yet no treatment is more
likely to be elucidated and ameliorated or cured if newborn
screening gives the medical community an accurate picture of
the prevalence of the disorder as well as early access to as many
of its sufferers as possible.51
The American National Institute of Child Health and Human
Development (NICHD) is already investing in this approach and is
‘expanding screening technologies and developing effective therapies
as concomitant activities’.52 This has contributed to some researchers
pleading for replacement of current neonatal screening tests (parti-
cularly tandem mass spectrometry, a technology not based on
genotype, but on the concentration of substances in the blood) with
screening using DNA chips.53 The NICHD is considering step-wise
expansion of neonatal screening to include conditions with known
mutations for which experimental, innovative therapies are being
developed. In principle, all clinically relevant genetic abnormalities,
including those that only lead to disease later in life, qualify for
inclusion in the test panel:
The technology could be expanded to screen for additional
disorders as mutational analysis or other multiplex technology
become available, with decisions being based more on what not
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to screen for (perhaps Huntington’s disease) than on what to
include.52
In this approach, the scope of neonatal screening is primarily
determined by the research agenda of genomic medicine and the
technological capacity to realise it. This agenda demands screening
that is as broad as possible. The authors acknowledge that all manner
of other abnormalities will be found with uncertain health implica-
tions for the child. However, they emphasise, the goal is to broaden
knowledge about these findings: ‘as our understanding of the function
of the DNA sequences increases, we should see an increase in the
accuracy and predictive power of the tests’.52
As soon as affordable WGS allows analysing the entire genome for
all newborns, this would appear to be the next logical step in this
research-driven approach. After all, testing for pre-selected genetic
abnormalities alone is not enough to fully understand the relationship
between genotype and phenotype. WGA allows research to start from
the other end of the spectrum and track relevant risk-increasing
or -decreasing factors in unexpected parts of the genome. This is
expected to generate a better understanding of both common and
rare conditions, enabling better, personalised treatments to be devel-
oped. This requires large-scale research databases (biobanks) that can
be used to examine associations between specific genotypes and health
data from individuals in various phases of their lives, starting at birth
or even before.51,54
Finally, the PCBE notes there is social pressure from parent
organisations of affected children as well as consumer organisations
in healthcare to broaden the scope of the current heel prick
screening. The report observes that there is broad support among
the American public for the idea that parents simply have the right
to all available genetic information about their child.51 The out-
comes of a recent American study among a large group of parents
with underage children support this assertion. A full third of
respondents said they would be interested in genetically testing
their youngest child for severe, untreatable late-onset conditions.55
The authors correlate the findings with penetration of the message
broadcast by commercial parties that genetic testing is an issue of
‘rightful ownership of one’s personal health data’.
The fact that the data belong to the child – that it’s someone else’s
data – is a distinction these companies prefer not to address in their
marketing strategies. Instead, they appeal to the parents’ sense of
responsibility. The implication is that parents not only have the right,
but also the moral duty to obtain information about the genetic
makeup of their children:
What to eat, what to avoid, what to talk to your doctor about –
think what you may have done differently with access to your
genetic information when you were younger. Having your child
take a genetic test at an early age can help him or her lead a long
and healthy life, making informed decisions about their health.
(http://www.mygenes-mychild.com/articles/childs-genetic-
information/index.php).
The PCBE emphasises that these three factors: the logic of the
concept of personalised medicine, the research importance that
results from the development of said concept, and the broad support
among the American public for the idea that parents have the right to
know as much as possible about their children’s health prospects,
potentiate each other to such a degree that ‘it may, in fact, prove
impossible to hinder the logic of genomic medicine from assimilating
the currently limited practice of newborn screening to its all-embra-
cing paradigm’.51
Expansion of neonatal screening: what are the limits?
In the Netherlands, current heel prick screening focuses solely on
conditions where timely treatment or prevention (often a diet) can
prevent significant health harm to the child.56 This is consistent with
the traditional principle that screening of newborns can only be
justified if the child may expect to benefit directly.57 However, this
principle is under pressure. There have been voices advocating
screening for untreatable conditions of early childhood for some
time. This could not only make it easier to understand early symptoms
(avoiding a stressful medical hunt for a diagnosis and allowing
immediate adequate care to be provided), but also provide important
information to parents who wish to have more children.58 If they know
their child has a severe hereditary condition, they can take the odds of
it occurring again (usually 1 in 4) into account when making future
reproductive choices. The debate on this subject is ongoing, but
support appears to be growing for the position that neonatal screening
for untreatable conditions that (also) benefits parents or the family as a
whole is not per definition unacceptable, as long as the child itself does
not suffer any negative consequences thereof.16,59
The latter implies that potential broadening of screening would
solely encompass the conditions of early childhood. Further broad-
ening of the scope could easily harm the child’s right to autonomy. At
present, this limit (diseases of early childhood) does not appear to be
threatened in the Netherlands. However, current technology (tandem
mass spectrometry) does not allow such further broadening of the
scope. In the meantime, DNA chips can track down diseases that meet
the current criteria, but cannot be identified using current technology.
The question remains what will happen when the switch is made to a
test based on genome-wide screening for technical or financial
reasons.53,60 Adhering to the principle that only (treatable) conditions
of early childhood may be screened for, this means filters will need to
be used during analysis to prevent information about the whole
genome from becoming available. Once again, the question becomes
not what should be tested for, but rather what should not. Whether
public opinion will be immune to the belief that parents have the right
to all possible information that such a genome-wide test can provide
about their child remains to be seen. Even the current limitation to
severe but treatable conditions has been criticised as a violation of the
right of parents to ‘decide for themselves whether they want to have
their child screened for more conditions’.61,62 All told, it is not
unthinkable that pressure will increase to move beyond the boundary
of early childhood diseases in the future.
PRENATAL DIAGNOSTIC TESTING AND SCREENING
It is easy to imagine the thousand-dollar genome affecting genetic
testing during pregnancy. This section addresses the dynamics of
current developments in the field of prenatal diagnostic testing and
screening. There is also a tendency towards increasingly broad-scope
testing.
Genome-wide prenatal diagnostic testing
Genome-wide (array CGH-based) tests are already used in prenatal
diagnostic testing, specifically to help assess unclear findings during
structural ultrasound imaging (20-week ultrasound). This form of
diagnostic testing requires obtaining cell materials via amniocent-
esis. The goal is comparable to that of postnatal use of genome-
wide diagnostic testing to elucidate the genetic background of
unexplained mental retardation or other abnormalities for which
it is unclear where precisely the genetic cause needs to be looked
for, as described in the section ‘Diagnostic testing’. Prenatal diag-
nostic testing of this type is more difficult, because there is no way
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to determine the child’s phenotype. It is conceivable that whole
sequence analysis will eventually also be used in this field. The
context is different, however. The structural ultrasound imaging is
performed at a gestation period of about 20 weeks. This is a
screening ultrasound offered to all pregnant women, during
which all kinds of structural abnormalities may be seen, as well
as some abnormal findings for which the exact meaning remains
unclear. The goal of this ultrasound includes providing the preg-
nant woman with additional information that she may use to
determine whether to carry the pregnancy to term or terminate
it.41,63 Implementation of genome-wide diagnostic testing to
help interpret unclear findings during the 20-week ultrasound
allows the pregnant woman to be better informed about the
potential nature and severity of any condition or handicap in her
unborn child. At the same time, it is clear that such testing can also
yield outcomes that make the decision facing the pregnant woman
(or couple) even more difficult, for example if the condition found
is mild, or only sometimes – but nowhere near always – leads to
severe symptoms.
Genome-wide (array CGH-based) diagnostic testing is also used for
a specific outcome of screening for Down syndrome, a significantly
thickened neck fold (43 or 3.5mm). This screening outcome must
take into account a broad spectrum of potential submicroscopic
chromosomal abnormalities that can lead to extremely severe condi-
tions.64 Here too, the objective is to provide the pregnant woman (and
her partner) with the best possible information about potential fetal
abnormalities, allowing a well-considered decision to be made about
whether or not to continue the pregnancy. If the decision is made to
carry the pregnancy to term, obstetric and perinatal care can be
offered based on the outcomes of the diagnostic testing in order to
provide the child with optimal support.
Genome-wide prenatal screening
In the meantime, the use of array CGH is being discussed as an
alternative to current microscopic chromosome testing (karyotyping)
for pregnant women who have undergone chorion villus sampling or
amniocentesis solely due to an elevated risk of Down syndrome or
other trisomic conditions.65 This is different from the situation
described above (clarifying outcomes of the 20-week ultrasound,
significantly thickened neck fold) as there is no indication for broader
screening in this group. The elevated risk of Down syndrome or other
trisomic conditions is an indication for diagnostic testing of the
chromosomes in question, but does not (unless a significantly thick-
ened neck fold is present) require testing for other chromosomal or
genetic conditions. When viewed in this context, the current karyo-
typing method already has a broader scope than necessary, which
recently led to the proposal to replace it with a more targeted test
looking only at trisomy 21 and a few other forms of aneuploidy.65–67
If other parties68–70 then propose a broader test, this is essentially a
plea for additional prenatal screening (The test is itself diagnostic;
nevertheless, as this would relate to a routine offering without specific
medical indication, it would constitute offering a test for screening
purposes.35,63), to be offered to women who already qualify for a
(expensive and not entirely risk-free) chorion villus sampling or
amniocentesis due to an elevated risk of having a child with Down
syndrome. In the United States, where women without an elevated risk
of having a child with Down syndrome (or a specific indication for
prenatal diagnostic testing) who want to be tested can undergo a
chorion villus sampling or amniocentesis,71 this type of array screen-
ing could become available to all pregnant women (who can afford it).
This is already the case in a few select centres. In a plea to broaden the
scope of prenatal screening, American geneticist Beaudet justified it as
follows:
If we are committed to offer prenatal diagnosis for Down
syndrome, we should be prepared to offer it for other disorders
of similar or more severe disability unless the risks or costs are
prohibitive.72
As long as invasive procedures (chorion villus sampling, amnio-
centesis) are required to obtain the fetal testing material, the associated
costs and the risk of miscarriage will present as an important limiting
factor. Although important steps are being made towards developing
non-invasive pre-natal testing methods using fetal DNA in maternal
blood (non-invasive prenatal diagnosis73,74), the question remains
whether the technology will be usable for genome-wide screening or
diagnostic testing. Should this be the case, it will become possible to
offer genome-wide prenatal tests to all pregnant women at an early
stage of the pregnancy as a risk-free one-step screening.75,76
Practically no research has been done to determine whether preg-
nant women would want such a genome-wide test. In an American
study, pregnant women who (for various reasons) qualified for an
amniocentesis or chorion villus sampling were given the option of
having an array CGH test performed in addition to the standard
karyotyping for no additional cost. Of the 45 pregnant women, 33
agreed to the offer. The most commonly listed reason was the desire to
obtain as much information about the fetus as possible. The women
who rejected the test did so because they were afraid of additional
worries, and because they felt the additional conditions that might be
found were extremely rare.68,77,78 Of course, array CGH is not the same
thing as a full sequence analysis, but as soon as the costs of WGS no
longer present a barrier, it is not unlikely that further expansion in that
direction will be advocated. Those who want to obtain (and to provide)
‘as much information as possible about the fetus’ will eventually no
longer be happy with anything less than the complete genome.
Practical courses of action: the more choice, the better?
The goal of prenatal screening for fetal abnormalities was defined as
follows by the Health Council: to enable pregnant women (and their
partners) to become aware of the potential presence of the condition
in question in the fetus, and to use such knowledge to make an
informed decision about whether or not to carry the pregnancy to
term.63 The justification of the screening offerings lies in providing
reproductive choices (practical courses of action) that would other-
wise not be available to the parties involved. What remains unan-
swered is the question of how broad the scope of these offering should
be.67 The developments discussed above mean debate on this subject
in the near future is inevitable. What conditions should prenatal
screening be offered for, and who gets to decide? Does the goal of
promoting reproductive autonomy imply the pregnant woman should
have the greatest possible number of choices and thus – if she states
she wants them – should be informed about as many other conditions
the fetus may have as possible in addition to the presence of Down
syndrome? Or does this lead to her having to process too much
information, making a well-informed decision about whether or not
to continue the pregnancy more difficult rather than easier?79
The broader the test, the more diverse the potential outcomes, the
more difficult it will be to enable the pregnant woman to provide true
informed consent. This issue is currently most pressing within the
context of the 20-week ultrasound.63,80 As it is not realistic to discuss
every possible outcome of the ultrasound with the pregnant woman
in advance, the question arises whether a form of generic consent
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(see section ‘Diagnostic testing’) would suffice. The best approach to
pre-test counselling is currently still being searched for. However, if the
possibility exists to perform genome-wide testing of the fetus, starting
with techniques such as array CGH, this challenge will only grow. The
core question is whether the goal of prenatal screening (promoting
reproductive choice) is served or actually undermined by the trend
towards broader prenatal testing.
Given these developments, it has been suggested that this will
eventually lead to almost every pregnancy delivering a finding that
forces the pregnant woman to decide on whether or not to abort, even
if only because of a finding whose meaning is not yet clear. The
paradox is that ‘the quest for a healthy baby could cause parents to
have no baby at all’.75 There is certainly cause for concern about the
degree to which increasingly broad prenatal tests, due to the some-
times difficult-to-interpret meaning of certain findings, may lead to
unnecessary abortion decisions. Regardless, future parents will often
still decide to have the child, even if they have been informed about
(potential) weaknesses in its genome. Most pregnancies are desired
and ‘valuable’, after all.
Testing of future children
Precisely because knowledge about the fetal genome will often not lead
to termination of the pregnancy, a new and until now unacknow-
ledged problem presents itself: children born after genome-wide
diagnostic testing or screening have already undergone far broader
genetic testing than is considered justifiable for neonatal screening.
Prenatal arrays can, for example, show that the future child has a
genetic susceptibility for severe late-onset disease, such as hereditary
breast cancer. Further expansion based on WGS may lead to children
being born with a fully analysed genome. Everything allowed for by
the current state of knowledge regarding the meaning of their genetic
makeup for health prospects and traits partially governed by genetic
factors (behaviour, cognition, personality) is in principle already
known. This raises the same concerns associated with analysing the
whole genome of newborns: the future child may not only be seriously
harmed, but he or she will also be robbed of the choice to decide for
him/herself, later in life, as an adult, what he/she wants to know about
his or her genome.
EMBRYO SCREENING
The introduction of increasingly broad testing may also be
expected for screening of embryos created in the context of an
IVF treatment. As broader tests become available, the question
arises of which criteria should be used for selecting embryos that
qualify for implantation in the uterus. Do doctors and future parents
have the responsibility to choose the embryo with the best health
prospects?
Pre-implantation genetic screening
In general, IVF produces more embryos than can be placed into the
uterus responsibly in a single cycle. In order to limit the number of
multiple births, only one or two embryos qualify for transfer per cycle.
The best embryos are selected for this purpose; the rest – assuming
they are of sufficient quality – can be frozen for a future attempt.
When viewed in this context, embryo selection is as old as IVF
treatment itself. Until recently, most centres selected primarily on
morphological characteristics that appeared to be associated with a
chance at a successful implantation in the uterus and therefore
pregnancy and birth. However, because many IVF embryos have
been found to have chromosomal abnormalities, and because (some
of) these abnormalities correlate strongly with failed implantation and
miscarriage, some centres started testing IVF embryos for relevant
abnormalities (aneuploidy of certain chromosomes) over 10 years ago,
and only transferring those without abnormalities to the uterus.81 The
same procedures developed for examining the embryos of couples
with an elevated risk of transmitting severe hereditary conditions to
their offspring are used: PGD. However, unlike PGD (targeted testing
with a specific indication), this is a routine test applied to all IVF
embryos. In order to make the distinction clear, this is referred to as
PGS, embryo screening in short.82 The procedure is the same,
however: in both cases, the embryo is sampled in a phase of
‘embryonic cleavage’; a cell is removed, examined, and if the outcomes
are favourable the embryo qualifies for transfer to the uterus.
In countries with commercial IVF practices, PGS has fast become a
routine part of IVF treatment, particularly in the treatment of older
pregnant women, in whom the percentage of embryos with chromo-
somal abnormalities is already highest. To date, more than ten trials
have been performed showing PGS has no advantages whatsoever.81
One possible explanation is the high percentage of mozaicism in
embryos in the blastomere phase (cleavage-stage embryos). Mozaicism
means that abnormalities found in the sampled cell may not be
representative of the embryo as a whole.83 Consequently, PGS also
leads to the rejection of embryos that do have a good chance of
implantation. Introduction of the current approach therefore appears
to have been premature. It has been proposed to investigate whether
PGS does work if embryos are sampled at a slightly earlier or later
stage (polar body and/or trophectoderm biopsy), but also to perform
analyses using the broader testing options offered by array CGH. This
is already being done in some clinics84 and a multicentre trial has been
set up by the European Society for Human Reproduction and
Embryology (ESHRE) to determine the value of PGS based on
polar-body biopsy and analysis with array CGH.81
Using microarray PGS, targeted testing of chromosome regions and
genes important to implantation and the odds of pregnancy can be
performed. This is the original and still the most important goal of
PGS. As soon as such a broader test is used for PGS, however, this will
also create the potential for looking at all manner of other hereditary
characteristics. Despite practical limitations relating to the
limited amount of time, and the fact that there is so little test material
(a single cell), some expect it will – in principle – be possible to test
embryos for:
 genes and chromosomal abnormalities that are important for the
odds of implantation and the chances of a successful pregnancy;
 other chromosomal abnormalities, such as Down syndrome;
 monogenetic abnormalities, including conditions that manifest
early in life, but also late-onset diseases such as Huntington’s
disease;
 genetic risk of multifactorial diseases, such as type 1 diabetes or
asthma;
 genetic susceptibility associated with certain non-disease-related
traits.85
Initially, this will only involve genome-wide screening based on
array CGH, but this is another area where implementation of genomic
sequence analysis is conceivable, possibly with some form of
filtering.86 To allow this, current techniques for genetic testing of a
single cell will first have to be improved significantly.
Selection of the ‘best embryo’?
To the extent that the PGS searchlight is set to a broader sweep, the
goal shifts from selecting the embryo with the best chances of growing
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into a child, to the embryo most likely to grow into the healthiest
possible child, to the embryo that will be the best possible child (with
the definition of ‘best’ and who gets to decide on it remaining open
for debate).
As there is always only a limited number of embryos available for
selection, and because some of them are rejected already due to quality
concerns relating to the odds of implantation and pregnancy, the
room for selection based on other characteristics considered relevant
remains limited. However, even if only two or three embryos remain
after this initial selection that qualify for transfer to the uterus, it can
still be useful to consider which one scores best on other criteria
believed to be important.
The broader the scope and the more stringent the desired selection,
the fewer the IVF embryos that will qualify for transfer to the uterus.
There is a real possibility that among the available embryos with an
acceptable chance of successful implantation, not one is present
without any potential risks to the child’s future health. This may
lead to doctors and parents deciding to initiate a new IVF cycle,
hoping this will lead to better embryos. Whether this can be justified
will depend on the nature of the risks identified, and the proportion-
ality of a new cycle (taking into account the associated material and
immaterial costs) as a means for preventing the said risks. And should
this be limited to one new cycle, or can it be repeated as often is
necessary until a good enough embryo is found? The immaterial costs,
in addition to the burden and risks of a new stimulation cycle for the
woman, include the larger number of embryos that will be necessary
to fulfil the couple’s desire for children.
It is clear this may lead to difficult choices and potentially to
conflict between parents and doctors in daily practice.87 If a choice has
to be made between multiple embryos with a good chance of
implantation, what should the criteria for making this choice be?
Should health aspects be the only things considered, and if so, which
ones? Can the choice remain meaningful if genome-wide testing is
involved? Should the choice be left to the parents, or does the doctor
have a separate responsibility in this area? What if parents want to
select based on non-health-related traits of the embryo, such as
gender? Is this unacceptable in principle? Or only if it involves a
form of selection that violates the right of the child to an open
future?48
As is the case for genome-wide prenatal diagnostic testing and
screening, the question arises whether this open future is not already
threatened by analysing the entire genome of embryos that may be
selected for transfer. How does this relate to the future individual’s
right to eventually decide for himself what he wants to know about his
genetic makeup?
FAMILIAR FRAMEWORKS UNDER PRESSURE
The legal, ethical and social questions raised by the development of the
thousand-dollar genome are not all new. What is new is that these
developments appear to have consequences for the normative frame-
works that guide policy on genetic diagnostic testing and genetic
screening.
Familiar questions on a different scale
Seven years ago, in an early commentary on the search for the
thousand-dollar genome and the normative implications thereof,
American ethicist and jurist Robertson wrote that not only would it
be another 10–15 years before technology was ready for fast and cheap
analysis of the entire genome, but also that by that time, scientists ‘will
know a great deal more about what genes do and their connections
with both single gene and multifactorial diseases’. Once the technology
becomes available, it will lead to ‘the same ethical, legal, and social
issues that now arise with our more fragmentary knowledge of the
genome and our more limited genotyping ability’.88
However, the reality of 2010 is that clinical introduction is already
knocking at the door, while knowledge about the precise function of
the genome remains extremely limited. The first steps are currently
being taken. It is expected that in 2011, a few hundred Dutch patients
will undergo whole-exome sequencing for the purposes of genetic
diagnostic testing (Professor RA Wevers, University Medical Centre
Nijmegen, personal message). It is therefore not true that the society
will have to deal with the implementation of the thousand-dollar
genome only after the issue of noise has been resolved, the advantages
(in terms of personalised medicine) are clear and the only thing that
needs to be clarified is how to prevent certain undesirable conse-
quences. This ignores not only the medical reasons currently leading
to genome-wide diagnostics, but also the driving forces and motives
behind the movement towards increasingly broad screening of
newborns, young adults, fetuses and embryos.
And what about Robertson’s comment that the implementation
of the thousand-dollar genome in daily practice will not raise any
new normative (ethical, legal) questions? It is true that problems
surrounding unsought and potentially unwanted findings, the
feasibility of informed consent, the right to not know, informing
relatives, recontacting, whether or not to test children, and so on
already exist now. If there is something new here, it is primarily a
question of scale: implementation of genome-wide testing makes
the challenges bigger and more complex. This means old answers
may not suffice, or new solutions may need to be sought. For
example, can the generic consent model be elaborated to allow for
meaningful consent for genome-wide diagnostic testing? Or is the
idea that well-considered consent will remain possible for tests that
can reveal information about the entire genome an illusion? What
does this mean for the acceptability of such tests? Is giving up on
anything more than marginal informed consent the price we have
to pay in order to benefit individually and as a society from the
advantages of personalised medicine?
A second marginal note to Robertson’s comment is that what is seen
as a relevant ethical or legal question or consideration is partly
dependent on the normative frameworks that form the perspective
we normally use to thematise certain issues. The previously outlined
development shakes up these frameworks and puts them under
pressure. This means that, unlike what Robertson suggests, how the
implications of the developments described in this report should be
dealt with is far from self-evident.
Diagnostic testing with additional findings, or screening with a
diagnostic indication?
A key distinction that will be put under pressure by the introduction
of the thousand-dollar genome is that between diagnostic testing and
screening. The former is conducted within the context of individual
patient care, in response to a complaint, based on previous findings or
family history; the latter encompasses the unrequested offering of
medical testing to an as yet healthy population. If genome-wide
analysis is used because it is the only way to determine the genetic
background of a poorly understood health problem in an individual
patient, the motive remains diagnosis. However, given the fact that at
most a tiny amount of all health information this delivers will have
anything to do with the specific problem being investigated, the
procedure also closely resembles a form of (undirected) screening.
Practically all findings relevant to the subject’s health prospects will,
after all, not have been specifically searched for.
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This is important when considering the question of what pers-
pective should be used to examine the justifiability of (offering) such
testing. Is this diagnostic testing with inevitable additional findings? In
this case, the key question is whether the approach selected is the best
way to obtain information about the health problem in question, and
a pragmatic solution will need to be found for how to deal with all
additional information yielded by the study. The question is whether
these outcomes can be termed ‘additional findings’ if they encompass
almost all of the test outcomes. Would it not be better to refer to it as
genome-wide screening with a diagnostic indication? That this for-
mulation, given the previously mentioned definitions of diagnostic
testing and screening, comes close to being a contradictio in terminis, is
not merely an issue of semantics. It shows that the familiar borders
between these different forms of medical testing are under pressure
due to the developments described, with potential implications for
normative assessment thereof. If these tests are (also) a form of
screening, should they not be assessed from within the normative
framework developed for screening (see the next subsection)? At the
very least, should not the question be asked whether the importance of
elucidating the individual’s initial problem weighs more heavily than
the potential disadvantages of genome-wide testing? Is this a con-
sideration that can be left to the patient? Even if this is the case, the
distinction between a ‘diagnosis perspective’ and a ‘screening pers-
pective’ may lie in the emphasis with which the consideration and the
potential implications of various outcomes are shared with the patient.
The issue becomes even more complex with genome-wide diagnostic
testing of (young) children. If this is also a form of screening,
the previously mentioned objections to genome-wide screening of
newborns and children come into play. Or does the fact that medical
diagnostic need was the indication for the genome-wide testing
change things in these particular cases?
That genome-wide diagnostic testing is difficult to differentiate
from screening and raises a number of difficult questions traditionally
associated with the normative framework developed for screening at
the very least means that the move towards genome-wide diagnostic
testing demands even more explicit justification in terms of medical
necessity, proportionality and subsidiarity. The latter means genome-
wide diagnostic testing should only be considered if it is clear that
testing with a narrower scope (using filters) will yield insufficient
results.
Genome-wide screening in the context of the existing normative
framework
Screening is defined as: ‘the provision of medical testing to persons
who in principle have no health complaints, focused on early
identification (or ruling out) of already present disease, hereditary
predisposition for disease or risk factors that increase the odds of
disease’.16 Conditions for responsible screening were first formulated
in the 1960s by Wilson and Jungner for the World Health Organisa-
tion, and later developed and modified further by various authors and
organisations (including the Health Council35), primarily taking into
account developments in the fields of genetic and reproductive
screening. The Health Council advisory report ‘Screening: between
hope and hype’16 summarises the key principles as follows:
 screening must be focused on a significant health problem;
 benefit: it must be clearly established that early detection of the
illness(es) or condition(s) in question (or: detection of medical
conditions such as carrier status or risk factors) can lead to a
significant reduction in the burden of disease in the target group in
question, or to other outcomes useful to the participants in the
context of the medical problems to which the screening relates;
these advantages must clearly outweigh the disadvantages that
screening can always have (for themselves or for others);
 reliable and valid instrument: the screening method must have a
solid scientific basis and the quality of the various parts of the
screening process must be guaranteed;
 respect for autonomy: participation in screening and follow-up
tests must be based on an informed and free choice; supply and
performance must respect patients’ rights (in the case of services
offered outside the healthcare system: consumers’ rights);
 appropriate use of resources: the use of available healthcare
resources in connection with and because of the programme
must be clearly shown to be acceptable in terms of cost-effective-
ness and justice.
Where does genome-wide screening fit into this framework? Gen-
ome-wide screening is defined as: analysing the entire genome
(ultimately based on a full sequence analysis). In order not to make
the discussion more complex than necessary, we are basing the
following on a scenario where such screening would be offered
routinely to (young) adults. Specific questions relating to neonatal
screening and screening of fetuses or embryos are addressed later in
this section.
The first condition, that screening must target a significant
health problem, can strictly speaking not be met as this form of
screening does not target a specific condition (or conditions).
This also strains the other conditions outlined in the normative
framework. To begin with, the question of utility (the second
condition in the framework in question). Some of the findings
can lead to immediate health gain or gains later in life, or
allow avenues for action viewed as useful by the party involved,
for example, lifestyle changes or reproductive choices. However,
the information will inevitably also include findings that are a
burden to the party involved, even potentially harmful (in a social
context) information about a predisposition for or chances of
developing serious, untreatable conditions, information about the
genetic basis for non-health-related traits, as well as findings of
which the precise (health) implications are unclear or unknown.
Given these potential outcomes, how do we determine whether the
advantages outweigh the disadvantages for the individuals to be
tested?
When weighing the disadvantages, the potential consequences of
imperfect testing methods must be considered, including unnecessary
worry and other negative consequences (unnecessary follow-up
testing, unnecessary preventive measures, unnecessary costs) of
false-positive outcomes, overdiagnosis and false reassurance caused
by false-negative outcomes. This is why a reliable, validated instru-
ment is necessary (the third condition from the normative frame-
work). How should this condition be assessed with regard to
sequencing and analysing the entire genome? First, it is important
to note that sequencing has its limitations, certainly using current
techniques. This means potentially relevant information (such as
translocations and other structural variation) may not be found.89
Second, because the analysis examines a broad array of not always fully
well-understood, more or less rare health effects, the question of
testing method validity and predictive value for outcomes does not
have an easy answer. Some findings are directly predictive, while the
predictive value of many others, particularly with regard to common
conditions, will be slight at best.36 Third, as interpretation of results is
reliant on still limited, but, thanks to new research, growing knowl-
edge about various forms of genetic variation, some conclusions, for
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example regarding personal health profiles and health recommenda-
tions, will have to be adjusted as new insights are gained.89 This speaks
directly of another quality aspect: post-test counselling and care for
people who have had their genome analysed is likely the greatest
challenge related to this development.39
The fourth condition is that participation in screening must be
based on an informed, well-considered choice (informed consent).
Even if taking the time for routine, extensive multidisciplinary
counselling is a realistic option,89 obtaining anything beyond a form
of generic consent appears unfeasible. The information that would
need to be provided would have to generally outline the (1) types of
findings, (2) types of consequences (treatment options, reproductive
choices, preventive options, psychosocial and social risks, conse-
quences for relatives) and (3) limitations, including the fact that
new insights may lead to adjusting the conclusions. The question is
whether this is enough to allow a considered choice to be made about
the offer to analyse the personal genome. The ‘right to not know’ in
particular will be difficult to shape in this context.
The fifth and final condition from the screening framework relates
to the effectiveness of screening in relation to the burden it places
on collective means. There needs to be a positive balance between
yield – in terms of health gain or other useful options – and net costs.
When looking at costs, it is clear that one must look beyond the costs
of sequencing alone (the thousand-dollar genome), but also include
the costs of analysis, pre-test and post-test counselling, the costs of
follow-up testing and intervention, as well as any savings,
for example due to timely prevention (lifestyle adjustment) or
more targeted use of medication.16 As it is still practically impossible
to comment on most of these factors, this demand can currently
not be met.38,90
Undirected screening, clinical check or a right to information?
If analysing the personal genome should be viewed as a form of
screening, it becomes clear that the undirected nature of such a test
can strain the principles of the previously discussed framework.
However, not all participants in the debate are convinced this devel-
opment should be viewed from this perspective. There are two
competing perspectives. First, there is the ideal of personalised
medicine. The belief that explicit justification is required for providing
unasked for predictive medical testing to people who do not have any
complaints or other reasons to (want to) undergo such testing will no
longer be obvious for those who believe that it is in everyone’s best
interest to be aware of their health risks and that it is the responsibility
of the medical field to find out about these risks as a basis for an
integral form of health management. Viewed in this light, it is
easy to understand why publications about analysing the genome
of a 40-year-old man (see Analysing the personal genome) refer to the
clinical assessment of a patient,36,89,90 despite the fact he has no health
complaints and there was no concrete indication for medical testing.
Reasoning from the ideal of tailored medicine, everyone is a patient
from cradle to grave. The distinction between screening and patient
care then loses all meaning.
This (medicalised) way of looking at things does mean that an
interest is created (the patient’s interest in good care), which imme-
diately guides the debate about the usefulness of analysing the entire
genome in a particular direction. This is reflected by what is said about
the usefulness of the pharmacogenetic information obtained about the
‘patient’: data on genetic factors that lead to a better or worse response
to certain medicines.90 Note: the man in question does not use any
medication. Furthermore, such information could be searched for in a
targeted fashion as soon as certain medication appears necessary.
If this were considered screening, this consideration would at the very
least question the supposed usefulness of the procedure. This con-
clusion is not drawn here. On the contrary: the emphasis is placed on
the fact that the genome of this ‘patient’, in addition to 63 known
ones, also yielded six new genetic variants important for the response
to medication that would not have been found using a targeted
pharmacogenetic test (using current levels of knowledge).90 Of course,
this is an important discovery that can contribute to improving care
for future patients. But the focus here should be on the supposed
benefits for the individual. Only by labelling him as a patient
can it be maintained that these discoveries have yielded clinically
relevant information that contributes significantly to the usefulness of
analysing the entire genome.
There is also another way of looking at the issue, which is
propagated among others by commercial providers of genetic tests
and dovetails neatly with the previous viewpoint. The key issue is that
people who want to know should be able to gain knowledge about
themselves, and that there should not be unnecessary barriers in their
way. From this perspective, the normative framework – particularly
the requirement that the advantages of undergoing medical testing
must clearly outweigh the always present disadvantages – is viewed is a
problematic form of paternalism. Why should the individual in
question, after being informed fully, not be able to make this choice
himself? Does being able to obtain personal (genetic) information not
relate to every individual’s right to a private life, as recognised by the
European Convention for the Protection of Human Rights and
Fundamental Freedoms?
The Dutch Population Screening Act (WBO) has previously been
criticised in this context, as it states that a license is required for certain
forms of (potentially high-risk) screening, based on the requirements
outlined in the normative framework discussed above (in the previous
subsection). The previous debate was engendered by the total body
scan: undirected imaging screening using a CT scan or MRI. As no
license was issued, Dutch citizens who believe such a (regular) scan has
preventive value must travel abroad to obtain it. Reasoning from
within the normative framework for screening, the Health Council
took the position that as long as there is no scientific evidence for
clinical usefulness, the inevitably present disadvantages (false-posi-
tives, unnecessary worry, false reassurance, overdiagnosis, iatrogenic
harm) plead against issuing such a license.16,91 Others view the
protection strived for in the WBO as an unjustified limitation of
the individual’s right to know.92,93 It appears inevitable that this
debate will be revitalised as a market for analysing personal genomes
develops.
As long as personalised medicine remains a largely unfulfilled ideal,
and as long as the cost-effectiveness of analysing whole genomes
remains unclear, offering such testing using public means is not an
option. For this reason, the British Human Genetics Commission
views analysing personal genomes (in adults) as solely lying in the
domain of commercial parties, building on the already available
commercial offerings of SNP-based genetic susceptibility profiling.38
The committee follows the reasoning that this essentially relates
to not limiting the rights of individuals to obtain information about
themselves without good reason. In the Netherlands, the WBO
would require licensing for such commercial offerings as well, which
would need to be assessed within the normative framework discussed
above and would therefore not be issued easily.16 The resulting
de facto ban will be easy to circumvent by commercial parties
operating outside the Netherlands using home-collecting tests
(for which self-collected test samples such as cheek swabs or blood
must be sent to a laboratory).
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Reproductive and non-reproductive screening: no longer worlds
apart
Prenatal screening, embryo screening and preconception screening of
(young) adults for carrier status of recessive conditions are forms
of reproductive screening. Reproductive screening has the goal of
allowing involved parties to make useful choices with regard to
reproductive risks. This is a key difference compared to non-repro-
ductive screening, which (usually) has the goal of obtaining health
gains for the individuals being tested.
These distinct categories of screening are associated with diverging
normative frameworks. Non-reproductive screening focused primarily
on health gains (such as screening in youth health care, but also
existing population screening programmes for breast and cervical
cancers) is rooted in public health care: collective facilities focused on
reducing disease burden. The usefulness for society and for the
individual generally line up for this type of screening. Striving for a
high, positive response to the screening programme is not seen as
problematic as long as participation is voluntary and based on
informed consent. In the Netherlands, this requirement also applies
to neonatal screening. In some other countries, it is assumed that
parental consent is not required when it comes to screening for severe
conditions of early childhood that can easily be treated or prevented if
detected early enough. After all, parents can be expected not to
withhold such screening from their child.
Reproductive screening, on the other hand, traditionally has strong
roots in the context of individual genetic counselling and reproductive
counselling. In normative terms, this is a different world, with a strong
emphasis on the personal character of reproductive decisions (parti-
cularly: the decision on whether or not to carry the pregnancy to
term) and on the ideal of professional non-directiveness. The indivi-
dual’s personal, well-informed choice is not merely an important
precondition; enabling this choice is the primary goal of the screening
itself.41,63 At the same time, monitoring this is considered an impor-
tant challenge, because the interests of individuals and society are less
self-evidently in line than is the case for non-reproductive screening
focused on health gains. The potential that social goals (particularly
cost reduction by preventing the birth of handicapped children) could
undermine the goal of reproductive screening (enabling autonomous
reproductive choices) is generally seen as a significant threat to the
moral tenability of screening offerings.28,63,94 Finally, an important
distinction is that while non-reproductive screening for conditions
for which there is no treatment or prevention is considered
problematic, reproductive screening is often specifically focused
on such conditions. Non-reproductive screening for such conditions
is problematic because it is likely to cause test subjects more
harm than good; this could also affect the anticipatory autonomy
rights of a child.
Strain between normative frameworks in the screening of newborns. To
date the briefly mentioned normative frameworks for reproductive
and non-reproductive screening (essentially subframeworks of the
general normative framework for responsible screening described in
the section ‘Genome-wide screening in the context of the existing
normative framework’) existed side by side without many problems,
as the worlds generally did not overlap. This appears to be changing.
The first overlap is found in the previously outlined debate on
expanding neonatal screening to include conditions of early childhood
for which there is no treatment or prevention (see the section
‘Expansion of neonatal screening: what are the limits?). Given the
most important motive for expansion is informing parents of their
recurrence risk in another pregnancy, traditional non-reproductive
(focused on the health of the child) screening gains a reproductive
goal. This creates overlap between the above-mentioned normative
frameworks. While the traditional goal of neonatal screening is easy to
reconcile with a directive approach to parents who do not wish to have
their child screened, expanding screening offerings at least in part
relates to tests that may not be forced onto parents. Various com-
mentators have pointed out the risk of contradicting messages.95–97
Parents might believe that screening for untreatable conditions is
something they should not be allowed to abstain from. Conversely,
they might lose sight of the fact that at least part of what is offered is
not entirely non-committal.
Strain between normative frameworks in analysing personal
genomes. A second development that may lead to overlap between
the normative frameworks described is the hypothetical scenario of
analysing personal genomes as part of routine care upon reaching
adulthood.37 A single test procedure could then provide information
about both avoidable reproductive risks and information important
for the individual’s personal health prospects. As long as this is a
service focused on individuals who want to obtain important infor-
mation about themselves (see the section ‘Undirected screening,
clinical check or a right to information?’), tension between underlying
normative frameworks may not be an issue. Simply informing people
about their health risks would seem to dovetail neatly with the goal of
reproductive screening: providing practical courses of action. The
question is, however, whether what each individual does with this
information will be seen as a choice to be respected that society has no
say in. This does not appear likely. An inevitable implication of the
ideal of personalised medicine is that – even more so than is currently
the case – the emphasis will lie on personal responsibility for good
health. Advocates for this ideal are clear: ‘Personal choices have a
profound impact on your health, and they are your responsibility’.39
A more realistic elaboration of the scenario above is that analysing
personal genomes will (in part) become a public health instrument.
People will be expected not only to want to obtain relevant health
information about themselves, but also to use this knowledge to
improve their health prospects wherever possible. If this becomes the
dominant perspective, the question arises whether there is still room
to address information affecting reproductive choices, such as carrier
status for recessive conditions, in a completely separate way. Will it
still be self-evident that people must be allowed to make a choice ‘that
they themselves believe to be good and prudent’ when it comes to
reproductive decisions?42
Strain between normative frameworks in genome-wide prenatal
diagnostic testing and screening. A third development where over-
lap between existing normative frameworks is developing is the
potential introduction of genome-wide tests within the context of
prenatal diagnostic testing and screening. From the perspective of
the traditional normative framework, this immediately raises diffi-
cult questions. Is a true informed choice a feasible option for the
pregnant woman and her partner? Will genome-wide tests not lead
to abortion decisions based on outcomes for which the exact health
implications for the future child are still entirely unclear? Is this not
the polar opposite of providing practical courses of action? An
almost equally important question is not even raised in this
context: is it acceptable to analyse the whole genome of future
children, including all available information on health problems
that can be expected later in life? In addition to enabling future
parents to make useful reproductive choices, should not the
interests of the future child be considered?
The ‘thousand-dollar genome’
WJ Dondorp and GMWR de Wert
S22
European Journal of Human Genetics
That this child is yet to be born is irrelevant. After all, the interests
of the future individual can already be harmed during (or even before)
the pregnancy.98 In other contexts, increasing attention is being given
to protecting these interests – for example, where potential health
harm to the future child due to an unhealthy lifestyle of the pregnant
woman is concerned.99 It would therefore be inconsistent to ignore
this violation of the autonomy rights of future individuals that will
inevitably follow the introduction of genome-wide prenatal testing.
But in order to be aware of this problem, the perspective must be
broadened. An adequate ethical analysis requires the justification
for genome-wide prenatal diagnostic testing or screening also
to be considered from the perspective of the normative framework
applicable to the testing of children.
The problem in question is familiar from the debate surrounding
targeted prenatal testing for the gene for Huntington’s disease.28,100 If
the test has an unfavourable (positive) outcome, most parents will
choose to abort the pregnancy. If they do not, however, they will have
a child who – before birth – has already undergone a presymptomatic
test for an extremely severe and untreatable late-onset disease. Given
the previously mentioned consensus that it should not be allowed to
test children for such conditions, the question arises whether care
providers can offer prenatal diagnostic testing in a responsible manner
if a potential outcome is the birth of a child who is tested for those
conditions. The same problem arises for prenatal diagnostic testing for
a number of other autosomal dominant conditions, including the
hereditary (often early-onset) form of Alzheimer’s disease.101 The
solution chosen to address these complex situations, contrary to
standard practice for prenatal diagnostic testing, is to only allow
future parents access to the test on the condition that they intend to
ask for an abortion in the event of an unfavourable result.102 Of
course, conditional access to prenatal diagnostic testing does not mean
pregnant women can be forced to terminate the pregnancy in the
event of an unfavourable result.
Although the problem (obtaining information not limited to
diseases only occurring early in life or requiring early treatment or
prevention) is not entirely new, there are two important differences
compared to the past debate. First, genome-wide prenatal screening
(and diagnostic testing) engenders a ‘systemic’ problem that will apply
in all cases where the decision is made not to terminate the pregnancy.
Second, conditional access is not a workable solution in this case. After
all, once the entire fetal genome has been analysed, carrying the
pregnancy to term will inevitably entail a violation of anticipatory
autonomy rights. There appears to only be one solution to limiting
this rights violation wherever possible when implementing prenatal
tests based on WGS: using filters during analysis. The entire genome is
then sequenced prior to birth, but not fully analysed. Ideally, filters
should be implemented so that they only yield information about
conditions manifesting early in life or requiring early initiation of
treatment or prevention.
A question remains whether the distinction between genome-
wide prenatal diagnostic testing (for example, after an abnormal
20-weeks ultrasound) and genome-wide prenatal screening
(offered without indication) affects the justifiability of violating
anticipatory autonomy rights. This appears to relate to the
reason for choosing genome-wide diagnostic testing. Is the goal
solely to inform the pregnant woman (and her partner) as fully as
possible in order to allow a well-considered decision about whether
or not to carry the pregnancy to term? Or are the future child’s
health interests also at stake? The latter case creates different conside-
rations than if genome-wide diagnostic testing does not serve the
child’s interests at all.
Strain between normative frameworks in genome-wide embryo
screening. While prenatal tests can require one to choose whether
or not to allow a child to be born, embryo screening involves deciding
to let this specific embryo rather than that one to grow into a child.
This is a different type of choice. While terminating the pregnancy
(within legal limits) is rightfully seen as a highly personal decision
that in principle neither the care provider nor society have any say in,
this is less clear for the choice presented here.103 Assume there
are multiple embryos with equally good chances of successful
implantation. Is the choice of which embryo to place into the
womb morally neutral? This would be the case if we did not know
anything else about the embryos, but this is precisely what may change
with the introduction of genome-wide tests. Assume the entire
embryonic genome has been analysed. Could the parents and involved
care providers then not be expected to choose the embryo with the
best health prospects or the highest quality of life?104 Even if this is not
in the interests of the child itself (the child by definition cannot
be born with a better genetic makeup than it has), the question
arises whether there are social interests to consider. This also has
consequences for the question of how widely to cast the searchlight of
the test used for embryo screening. A narrow beam would mean
pre-emptively missing out on the possibility to select the embryo with
the best chance of a healthy and happy life. What about the doctor’s
role? In principle, prenatal diagnostic testing and screening demands a
non-directive stance from involved care providers. In this scenario,
however, the doctor is jointly responsible for the creation of the future
child.105 Does this make a directive approach less problematic? Can
the doctor present wide-scope (possibly genome-wide) embryo
screening as self-evident? Would it be acceptable for the society to
become involved in the process? What if insurance companies demand
optimum use is made of the possibility to select an embryo with the
best possible risk profile as a condition for covering the costs of
IVF?103
It is important to note that the choice between embryos cannot be
avoided. No pregnant woman and no future parents are obligated to
undergo prenatal screening. But having a child through IVF implies
embryo screening. After all, one (sometimes two) embryo will have to
be selected regardless. To date, this is based on morphological quality
criteria not extending beyond the odds of implantation and preg-
nancy. However, as soon as tests become available that can also be
used to select for a broad range of genetic factors relevant to the future
child’s health prospects, the question of what a good choice is, and
therefore what a good embryo is, cannot be avoided.
This gives rise to complex problems that require deeper
consideration. First and foremost, it appears the classic normative
framework for reproductive screening will be strained in this specific
context. The ideal of allowing autonomous reproductive choices
appears less suitable for guiding this new practice than the idea of
making future parents and care providers jointly responsible for
making a good choice. What criteria should apply to defining this
‘good choice’ remains the core issue. That society will primarily
want this question answered from a public health perspective is a
realistic assumption.
Second, the problem of testing future children and the potential
harm to their anticipatory autonomy rights appears to be an even
greater challenge in this context than with regard to genome-wide
prenatal diagnostic testing and screening. The use of filters could once
again be proposed as a solution to only obtain information about
conditions manifesting early in life or requiring early initiation of
treatment or prevention. But does not the idea of having to select
the best possible embryo stand diametrically opposed to filtering out
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information that may be relevant to health prospects, including long-
term ones, of the future child?
Blurring borders between care and research
As described in the section ‘Screening of newborns’, the plea for
further expansion of neonatal screening is in part coming from
researchers who expect that large-scale screening of newborns for all
kinds of rare conditions could make a significant contribution to
elucidating the causes of those diseases and the development of
treatments. The importance of such research (for society, for children
who could potentially benefit from the results of such research) is
obvious. But is it a valid reason for expanding screening of newborns?
According to the advocates for this approach, the answer is clear. They
see the classical assumption, that screening of newborns must benefit
the individual child as a barrier to scientific progress:
There is hope of developing and evaluating effective therapies
only with early presymptomatic identification of the disorder
and the availability of sufficient numbers of presymptomatic
patients with rare disorders that a registry can provide. The old
dogma cannot be allowed to stand in the way of developing
effective treatments for these rare genetic disorders.52
As this quote demonstrates, obtaining a research population that is
as large as possible appears to be the primary goal of the plea for
expansion. After screening, the next step is to include children with
specific genotypes in a large-scale research registry (genetic database,
bio bank) that can be used to study genotype–phenotype correlations.
The conditions under which children (with proxy consent from
their parents) can be included in bio bank research are still being
debated.54,106,107 The main issue here is that it becomes impossible to
determine where screening (healthcare) stops and scientific research
begins.51,108 The question of whether the trend towards increasingly
broad tests is in part driven by the need to obtain data for scientific
research also applies to other forms of diagnostic testing and
screening. As long as this is a supplemental goal that does not itself
determine the scope of the test, this does not have to be a problem.
The discussion above does demonstrate that the goals of healthcare
and science can easily cross paths. The same issue exists for com-
mercially offered direct-to-consumer tests: consumers often are
unaware that their data are being used for scientific research.109
CONCLUSIONS
Even if the question of whether all expectations raised by the ideal of
personalised medicine will be realised remains open, the developments
described in this monitoring report appear to have potentially
far-reaching consequences, not only for future developments in
healthcare, but also for individuals and society as a whole.
Genome-wide diagnostic testing can deliver useful information
about poorly understood diseases and improve the prognosis of and
treatment options for patients. But it will inevitably also yield all kinds
of unsought information that is potentially burdening or even harmful
for the patient (and his or her blood relatives). This raises the question
of what conditions must be met for responsible use of such testing. It
is currently insufficiently clear whether meaningful informed consent
is possible in this context, how the ‘right to not know’ can be given
form, and how the obtained information can be handled in a
responsible manner. The questions become all the more pressing
where genome-wide diagnostic testing of children is concerned.
Genome-wide screening, the analysis of the entire genome without
medical indication, appears to have more disadvantages than potential
advantages for the parties involved at this time. Offering such
screening as part of standard healthcare cannot currently be justified.
However, as WGS costs drop, commercial offerings based on
genome-wide tests are to be expected. The question is how this affects
the role of the government. Is its primary task in this context to
protect citizens from unsuitable screening, or should they be left free
to determine what information they want to obtain about themselves?
Where genome-wide screening of adults already leads to difficult
questions, the issue is magnified when it comes to children, for
example, in the scenario of genome-wide heel prick screening. The
question becomes not only whether parents can oversee the Pandora’s
box they are opening, but also whether they have the right to make
that decision for their children. An important distinction between
screening and genome-wide tests in the context of diagnostic testing is
that there is no indication for such a broad test in the screening
context. The potential benefit of analysing genetic characteristics that
may be relevant for all kinds of personalised medicine as early in life as
possible is itself not sufficient justification. Even if increasing under-
standing will make this a stronger argument in the future than it is
now, the question remains whether the intended advantages
outweigh the potential harm caused by burdening information or
information that can otherwise negatively affect the child in question.
Third party interests, including the desire of parents to know as
much as possible about the genetic makeup of their child, or those
of scientific research, may not play a decisive role when coming to a
decision.
Analysing the entire genome of future children may be the unin-
tended consequence of genome-wide diagnostic testing and screening
offered during pregnancy with the aim of facilitating an informed
abortion decision. The question is what the potential violation of the
child’s ‘anticipatory autonomy rights’ should entail for the accept-
ability of genome-wide prenatal testing. Does the distinction between
diagnostic testing and screening matter? The autonomy of the future
child is also affected by the potential widening of the scope of embryo
screening in the context of IVF. This involves the question of which
embryos qualify for transfer into the uterus. Do doctors (and future
parents) not have the responsibility to choose the embryo with the
best health prospects? Conversely: are they allowed to analyse the
entire genome of embryos that may grow into a child?
The questions raised by the discussion of the potential applications
of the thousand-dollar genome are not all new, although the scale of
the challenges is. More important is how this affects with the familiar
normative frameworks normally used to define and answer such
questions. They are under pressure, starting to overlap or run into
each other. Relative to the developments discussed in this monitoring
report, they appear to be losing at least part of their organising
capacity and guiding character. Although some of the developments
discussed are problematic when viewed from within these frameworks,
there is also room to ask whether a review or recalibration of these
frameworks is necessary, should we wish to continue providing
guidance for the application of scientific knowledge in healthcare.
Further reflection on the developments outlined and the normative
implications thereof for all parties involved, including clinicians,
scientists, jurists, ethicists, patient organisations and policy makers,
is of great importance. To begin with, there is a need for guideline
development by the professions involved in the application of
genome-wide diagnostics in adults, children and fetuses. The currently
most pressing question is how to responsibly deal with the unsought
for outcomes of such diagnostic testing. Given the complexity of the
matter, in both normative and scientific terms, there is also a need for
more comprehensive reflection and debate.
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